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Gas-liquid chromatographic methods for the simultaneous determination of eight 
active ingredients in cough-cold syrups and for the simultaneous determination of three 
alkaloids in pharmaceutical preparations have been developed. The active ingredients 
present in cough-cold syrups under study were bromhexine, chlorpheniramine, codeine, 
dextromethorphan, diphenhydramine, ephedrine/pseudoephedrine, guaiphenesin, and 
papaverine. And the alkaloids under study were atropine/hyoscyamine, homatropine, 
and hyoscine. 
In both methods, the active ingredients in cough-cold syrups or the alkaloids in 
eye drops, injections and tablets were first separated from the excipients with chloroform 
from alkaline medium before injection. 
The drugs extracted from the cough-cold syrups were separated by gas-liquid 
chromatography on a glass column (5 ft. x 2 mm. i.d.) packed with 3% OV-25 supported 
on Supelcoport (80/100 mesh). The column temperature was maintained at 170 for 
1 min.，then programmed to 265 at a rate of 10 °C/min., and maintained at this 
temperature for 10 min. and 1 min., respectively, for samples with and without 
papaverine. Clomipramine hydrochloride was used as the internal standard. 
The extracted alkaloids were resolved by gas-liquid chromatography on a glass 
column (5 ft. x 2 mm. Ld.) packed with 3% OV-225 supported on Supelcoport (80/100 
mesh). The column temperature was maintained at 220 °C for 1 min., then programmed 
to 260 °C at a rate of 15 °C/min.，and maintained at this temperature for 4 min. and 2 
min., respectively, for samples with and without hyoscine. Diphenhydramine 
hydrochloride was used as the internal standard. 
Al l the chromatographic signals were measured by a flame ionization detector， 
with an air and hydrogen flow rate of 300 and 30 ml/min., respectively. The nitrogen 
carrier gas flow rate was set at 30 ml/min. for both methods. 
The recoveries for analysis of drugs in the cough-cold syrups ranged from 96.0 to 
99.7%, and the relative standard deviations of ten replicate determinations ranged from 
0.49 to 4.7%. The method was applied to the determination of active ingredients in nine 
commercially available cough-cold syrups. 
The recoveries for the analysis of alkaloids ranged from 95.9 to 102.1%, and the 
relative standard deviations of ten replicate determinations ranged from L5 to 3.3%. 
Results are reported for seven commercially available pharmaceutical preparations, 
including eye drops, injections, and tablets. 
An established HPLC method has been modified to enable guaiphenesin in 
cough-cold syrups to be analysed by isocratic reversed-phase ion-pair high-performance 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 REVIEW OF GAS-LIQUID CHROMATOGRAPHY 
In 1941，the concept of gas-liquid chromatography (GLC) was first introduced 
by Mart in and Synge^^. In gas chromatography, the sample is injected and then 
vaporized on the head of a chromatographic column. Elution is brought about by the 
flow of an inert gaseous mobile phase. Different from most other types of 
chromatography, the mobile phase does not interact with molecules of the analyte, its 
only function being to transport those molecules through the packing. 
Gas chromatography is a technique for separating volatile compounds by 
percolating a gas stream over a stationary phased If the stationary phase is a liquid, we 
speak of Gas-liquid Chromatography (GLC). The liquid is spread as a thin f i lm over an 
inert solid and the basis for separation is the partitioning of the sample in and out of 
this l iquid film. The wide temperature range (up to 400 °C) of liquid phases makes 
GLC the most versatile and selective form of gas chromatography. 
The basic components for gas-liquid chromatography are shown in Figure 1.1-
l^b，and a description of each component is as follows: 
a. Carrier gas supplyib 
Carrier gases must be chemically inert, which include argon, helium, hydrogen 
and nitrogen. The choice of gases is usually dictated by the type of detector used. Flow 
rates of gases are controlled by a pressure regulator. Inlet pressures usually range from 
10 to 50 psi (above room temperature), which lead to flow rates of 25 to 150 ml/min. 
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Figure 1.1-1 Schematic diagram of a gas chromatograph. 
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b. Sample Injection System^^ 
Since column efficiency requires that the sample be of suitable size and be 
introduced as a "plug" of vapour, a microsyringe is used to inject liquid samples through 
a rubber or silicone diaphragm or septum into a heated sample port (or injection port) 
located at the head of the column. The injection port temperature is usually about 50 
°C above the boiling point of the least volatile component of the sample. For packed 
column, the injection volume is varied from a few tenths of microliter to 20 ijlI, 
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c. Columns 
Two types of columns are encountered in gas-liquid chromatography, including 
packed and capillary. The former was used in the research project and will be discussed 
in detail. Unlike open tubular column, the packed column can accommodate larger 
sample size and are generally more convenient to use. 
c.l Column dimensions、。 
Nowadays, packed columns are usually made by glass or metal (stainless steel, 
copper, or aluminum) tubes with lengths of 2 to 3 m and inside diameters of 2 to 4 mm. 
The tubes are usually in the form of coils having diameter of around 15 cm. 
C.2 Types of solid supports、。 
The solid support used to hold the liquid stationary phase in place so that as 
large a surface area as possible is exposed to the mobile phase. The most widely used 
supports for gas chromatography were prepared from naturally occurring diatomaceous 
earth. The solid support may be prepared by crushing, blending, and briquetting the 
diatomaceous earth as it comes from the ground followed by heating at over 900 
The resulting bricks are then ground and separated by scanning into particles having 
uniform diameters. An example is Chromosorb P. Alternately, the solid support (e.g. 
Chromosorb W) may be prepared by mixing the diatomaceous earth with a sodium 
carbonate flux before heating at about 900 °C The product is more rugged than the 
former, however, its specific surface area is only about 1 m^/g compared with 4 m^/g 
for the former. 
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C.3 Particle size of supports 
Although the column efficiency increases rapidly with decreasing particle 
diameter of the packing, the pressure difference required to maintain a given flow-rate 
of carrier gas varies inversely as the square of the particle diameter^^. This relationship 
has placed lower limits on the size of particles employed in gas chromatography since 
it is inconvenient to use pressure differences that are greater than about 30 psi. As a 
result, the usual support particles are 60 to 80 mesh (250 to 170 fim) or 80 to 100 mesh 
(170 to 149 Mm). 
C.4 Adsorption on solid supports、己 
Physical adsorption on support surfaces of polar or polarizable analyte species 
results in distorted peaks, which are broadened and often exhibit a tail. Adsorption is 
the consequence of the formation of silanol groups on the surface of silicate by the 
reaction with moisture. A fully hydrolysed silicate surface has the structure 
OH OH OH O H 
\ p p P / 
\ / \ / \ / \ / 
Si Si Si Si 
The SiOH groups have a strong affinity for polar organic molecules and tend to retain 
them by adsorption. 
Support materials can be deactivated by silanization with dimethylchlorosilane 
(DMCS) or hexamethyldisilazane (HMDS). 
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C.5 Stationary phase 
The ideal stationary phase in a gas chromatographic column should have the 
properties as follows:(1) low volatility; (2) thermal stability; (3) chemical inertness; 
and (4) solvent characteristics^^. Even though the choice of stationary phase could base 
upon polarity parameters of the stationary phase relative to those of the sample 
constituents, the optimal separation conditions can only be realized by trial-and-error 
experiments. 
McReynolds constants^® are symbolized by X，，Y，，Z，，U' and S'. Each is related 
to one type of interaction between a solute and the stationary phase, i.e. X ' = benzene, 
Y ' = 1-butanol, Z ' = methyl-n-propyl ketone, U，= nitropropane，and S'= pyridine. The 
magnitude of each of them provides a measure of the strength of this type of interaction 
for a group of compounds represented by the standard. For example, aromatics and 
olefins have the same polarity characteristics as benzene. As a result, compounds 
containing those functional groups will be most strongly retained by a stationary phase 
having a large value of X，. McReynolds constants are widely used to characterize the 
multitude of stationary phases that are now available. One of the important uses of 
McReynolds numbers is for recognizing similar liquid phases in order to avoid 
duplication of effort in testing the column efficiency for a given separation. 
d Detectorsif 
Numerous detectors have been investigated and used during the development 
of gas chromatography. However, only four have found widespread use, including 
thermal conductivity, flame ionization, thermionic, and electron capture. Details of a 
flame ionization detector is described here because it has been employed in the present 
research project. 
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The flame ionization detector (FID) was first introduced in 1958. Its high 
sensitivity, uniform response to hydrocarbons, and a broad linear range have made the 
F ID become one of the most popular measuring device used in gas chromatography. 
Use of the F ID is based on the measurement of variations in the ionization current in 
a hydrogen-air flame due to the presence of eluted substances. With a burner such as 
that shown in Figure 1.1-2，the charged species are attracted to and captured by a 
collector; an ion current results, which can be amplified and recorded. 
Figure 1.1-2 A typical flame ionization detector. 
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Although many questions about the flame chemistry in the F ID remain unsolved, 
it was suggested that the primary source of ions in the flame was produced through a 
chemical ionization caused by the reaction of an oxygen atom with a radical containing 
a single carbon^'"^. The most commonly proposed reaction is 
CH + O ~ ~ > CH〇+ + e-
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It is observed that the number of ions produced is roughly proportional to the number 
of reduced carbon atoms (or effective carbon number, ECN) i n the plasma. Funct iona l 
groups, such as carbonyl，alcohol, halogen, and amine, yield fewer ions or none at all. 
Besides, the detector is insensitive towards noncombustible gases such as H2O, COg, 
SO2，and NOx. This behaviour makes the flame ionization detector a most useful general 
detector for the analysis of most organic samples. 
Recently, Jorgensen et has attempted to develop a computer program that 
would query the user for structural information about each peak in a chromatogram, 
calculate the ECN from information in a data base, and use the area and concentration 
of the internal standard to calculate the concentration of the component. 
The performance of the flame ionization detector depends on the proper choice 
of gas flow rates5a. In general, good sensitivity and stability are obtained with a carrier 
gas flow of 30 ml/min, hydrogen flow of 30 ml /min and air flow at 300 ml/min. Figure 
1.1-3 shows the relation between FID sensitivity and hydrogen flow rate, and Figure 
1.1-45C shows the relation between FID sensitivity and air flow rate. In addition, the 
flame ionization detector exhibits a high sensitivity (about lO'''^ g/ml), large linear range 
(about 10^), and low noise. A demerit of the flame ionization detector is that it is 
destructive of the sample. 
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Figure 1.1-3 Relationship between FID sensitivity and hydrogen flow rate. 
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Figure 1.1-4 Relationship between FID sensitivity and air flow rate. 
f j / ^ 
V 
-f 1 1 1 1 1 1 
0 100 200 300 400 500 
Air Flow ml/min 
1.2 APPLICATION OF GAS-LIQUID CHROMATOGRAPHY IN DRUG ANALYSIS^ 
A l l drug analyses virtually require both identification and quantitation. In this 
regard, gas chromatography offers major advantages. The high sensitivity of gas 
chromatography is an important factor, especially in drug metabolism or toxicity studies, 
where only trace quantities of drug are available. High-resolution gas chromatographic 
columns allow excellent selectivity in the presence of structurally similar analogs or 
degradates. Besides, the ability of adjusting parameters such as carrier gas flow and 
column temperature enables the analyst to optimize selectivity. 
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Many drugs are non-volatile compounds. Besides, they contain relatively polar 
substituent groups which contribute to interaction with the solid support. In order to 
overcome these problems, derivatization technique was commonly used in the past two 
decades to prepare thermally stable and volatile compounds for gas chromatographic 
analysis. Cimbura and Kofoed^ had given a review of some GLC-FID derivatization 
techniques, including acetylation, methylation, and chemical reduction, which were found 
useful in forensic toxicology. Cruickshank and Sheehan® demonstrated the use of gas 
chromatography in analysis of 21 amino acids as their N-trifluoroacetylamino acid 
methyl esters. Parker et al^ described the chromatographic behaviours of 41 alkaloids 
on a column of 5% SE-30 at five temperatures. Besides, Kazyak and Knoblock^° 
illustrated the application of gas chromatography to analytical toxicology, and the 
chromatographic behaviours of 59 drugs on 1% SE-30 were reported. 
Nowadays, the advances in the development of new types of stationary phases 
allow the analysts to perform direct gas-liquid chromatographic analysis of drugs 
without preliminary or on-column derivatization. For example, Gibbs et a l ” and Rao 
1 o 
et al reported the use of GLC for quantitative determination of the active ingredients 
in pharmaceutical preparations as their free basic amine. 
1.3 AIMS OF THE PRESENT WORK 
The aims of the present work were to develop simple and efficient gas-liquid 
chromatographic methods for the simultaneous determination of active ingredients in 
cough-cold syrups and for the simultaneous determination of alkaloids in pharmaceutical 
preparations. 
The drugs under study were bromhexine, chlorpheniramine, codeine, 
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dextromethorphan, diphenhydramine, ephedrine, guaiphenesin, papaverine, and 
pseudoephedrine, which are commonly found in commercially available cough-cold 
syrups. The drugs were extracted with chloroform from an alkaline medium, and 
separated on a glass column packed with 3% OV-25. The details of the proposed 
method wil l be discussed in Chapter 2. 
The alkaloids under study were atropine, homatropine, and hyoscine, and 
hyoscyamine, that are usually found in eye drops, injections, and tablets. Those alkaloids 
were separated from the excipients with chloroform, and resolved by a glass column 
packed with 3% OV-225. The detailed descriptions will be shown in Chapter 3. 
An established HPLC method for quantitative determination of the active 
ingredients in cough-cold syrups had been modified for the purpose of checking the 
contents of guaiphenesin in cough-cold syrups. The results are reported in the Appendix. 
10 
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GAS-LIQUID CHROMATOGRAPHIC DETERMINATION 
OF ACTIVE INGREDIENTS IN COUGH-COLD SYRUP 
FORMULATIONS 
2.1 INTRODUCTION 
Bromhexine, chlorpheniramine, codeine, dextromethorphan, diphenhydramine, 
ephedrine, guaiphenesin, papaverine and pseudoephedrine are active ingredients 
commonly found in cough-cold syrups。Each of them possesses its particular functions^'^： 




Bromhexine is a mucolytic agent which changes the structure of bronchial 
secretions by rarefication and fragmentation of the mucopolysaccharide fibres, leading 
to a reduction in the 
viscosity of the sputum, 
12 
ii. Chlorpheniramine 厂 ci 一 
A 




Chlorpheniramine has the actions, uses and undesirable effects of the 
antihistamine drugs and is effective in smaller doses but it has no marked anti-emetic 
effect. 
i i i. Codeine 
N-CH3 
CH3.0 0' ' ' bH 
Codeine is an analgesic with uses similar to those of morphine but it is much 
less potent as an analgesic and has only mild sedative effects. It possesses very useful 




Dextromethorphan has a depressant action on the cough centre similar to that 
of codeine phosphate, but it has no analgesic or expectorant effect. Its use does not 
lead to addiction. 
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V. Diphenhydramine 
[(C6H5)2-CH-0-[CH2]2-NH(CH3)2] c i -
Diphenhydramine has the actions, uses, and undesirable effects of antihistamine 
drugs. It is one of the less active but more sedating of the group and is sometimes used 
for its sedative properties. 
vi. Ephedrine 
OH NH-CH. I • 二 
I I 
CsHs —C — C —CH3 抓 0 I t 
I > 
- H H 
Ephedrine is a sympathomimetic amine with direct and indirect effects on 
adrenoreceptors. 





Guaiphenesin is reported to reduce the viscosity of tenacious sputum and is used 
as an expectorant in cough mixtures and tablets. 
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viii. Papaverine ？. ch 3 
V 
Papaverine has little hypnotic or analgesic action. It is used occasionally to 
produce relaxation of involuntary muscles. 




一 ^ ^ 一 
Pseudoephedrine is a sympathomimetic amine with action and undesirable effects 
resembling those of ephedrine. It is used as a bronchodilator and peripheral 
vasoconstrictor in preparations for the relief of nasal and bronchial congestion, 
particularly in bronchial asthma. 
High-performance liquid chromatography (HPLC)^'® are commonly used for the 
determination of the active ingredients in cough-cold mixtures. Besides, derivative 
spectrophotometric methods^"^ and gas-liquid chromatographic (GLC) methods'^'^'''^ have 
also been developed for the analysis of these drugs, however, most of them could only 
quantitatively determine two or three components simultaneously. In addition, the 
methods involving the measurement of U V absorption were easily interfered by the 
excipients present in cough syrups, such as dyes and flavours. 
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The present work is to develop a simple and efficient gas-liquid chromatographic 
method for simultaneous determination of the eight* active ingredients mentioned above, 
individually or together, in various cough-cold syrup formulations after extraction of the 
active ingredients with chloroform. The optimum conditions for carrying out the 
extraction and for the measurements were determined. Nine commercially available 
cough-cold syrups were analysed for the contents of the active ingredients, and the 
results were compared with those obtained using high-performance liquid 
chromatography^. In performing the counter-check method, it was found that this 
method was also suitable for the determination of guaiphenesin in cough-cold syrup 
formulations after a minor modification, and the results are shown in the Appendix. 
Ephedrine and pseudoephedrine being stereoisomers have similar properties and are 




A Varian Model 3700 Gas Chromatograph equipped with a flame ionization 
detector, and attached to a Hitachi 833A Data Processor was used. 
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2.2.1.2 Gas chromatographic conditions 
A glass column (5ft. x 2 mm i.d.) was packed with 3% OV-25 on Supelcoport 
(80/100 mesh). The carrier gas was nitrogen with a flow rate of 30 ml/min. The flow 
rate of hydrogen and air were 30 and 300 ml/min., respectively. The injection port and 
detector temperatures were both kept at 270 The initial column temperature was 
kept at 170 for the first minute, then programmed to a final temperature of 265 
at a heating rate of 10 °C/min., and then maintained at this temperature for 10 min. 
and 1 min., respectively, for samples with and without papaverine. The attenuation 
was 1 in the gas chromatograph and varied in the data processor (8-10，depending on 
the injection concentration). The chart speed of the data processor was 2.5 mm/min. 
When not in use, the column was kept at 50 with a nitrogen flow rate of 30 ml/min. 
When broadening of the peaks was observed, which was an indication of decomposition 
of the packing material, the first few inches of the packing material near the injection 
port was replaced, and the column could be used for about six months. 
2.2.2 The Counter-check HPLC Method 
An established HPLC method^ was found to be suitable for checking the contents 
of all active ingredients under study except guaiphenesin in cough-cold syrups. With a 
minor modification of the HPLC method, it can be used to check the content of 
guaiphenesin in cough-cold syrups and the details of the modification are shown in the 
Appendix. 
2.2.2.1 Instrumentation 
The liquid chromatograph consisted of a controller (Beckman, model 421A), a 
solvent pump (Beckman, model HOB), an injection system (Altex, 210 valve), an 
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analytical column Beckman 5 m Ultrasphere-ODS 250 x 4.6 m m， i . d .， a detector 
(Beckman, model 163 variable wavelength) and an integrator (Beckman, model 427). 
The column was protected by a guard column packed with the same packing material. 
Instrumental settings 
Original For guaiphenesin 
Flow rate 1.3 ml/min 1.0 ml/min. 
Wavelength 254 nm 274 nm 
Chart speed 0.5 cm/min. 0.5 cm/min. 
Attenuation 16 16 
2.2.2.2 Mobile phase 
Composition of the mobile phase: 
Original For guaiphenesin 
Methanol 715 ml 635 ml 
Water 234 ml 315 ml 
Tetrahydrofuran 50 ml 50 ml 
Phosphoric acid (85%) 1 ml 1 ml 
Sodium dioctyl-
sulphosuccinate 5.8 g 5.8 g 
pH (adjusted by 
ammonia) 4.6 4.6 
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2.2.3 Reagents 
A l l drugs were of Pharmacopoeial or equivalent purity, and were used without 
further purification. A l l other reagents were of analytical grade. 
2.2.3.1 Aqueous internal standard solution 
Internal standard solution of clomipramine hydrochloride (1.502 mg/ml) was 
prepared by dissolving exactly 75.1 mg of the compound in 50 ml of distilled water in 
a volumetric flask. 
2.2.3.2 Aqueous stock solutions of the drugs 
Stock solution of bromhexine hydrochloride (2.50 mg/ml) was prepared by 
weighing exactly 125.00 mg of the drug in 50 ml of sulphuric acid (O.IM) in a 
volumetric flask. 
Similarly, stock solutions of chlorpheniramine maleate (1.02 mg/ml), codeine 
phosphate (5.00 mg/ml), dextromethorphan hydrobromide (3.12 mg/ml), 
diphenhydramine hydrochloride (5.00 mg/ml), ephedrine hydrochloride (5.00 mg/ml), 
guaiphenesin (15.63 mg/ml), papaverine hydrochloride (1.25 mg/ml) and 
pseudoephedrine hydrochloride (6.24 mg/ml) were prepared by dissolving appropriate 
amounts of the corresponding drugs in 50 ml of sulphuric acid (O.IM) in volumetric 
flasks. 
2.2.4 Aqueous Standard Solutions 
Various mixtures of drugs were prepared by mixing appropriate amounts of stock 
solutions of these drugs to match the active ingredients and their respective label values 
for each syrup. For example, for sample No. 4 in Table 2.3.6-2 (page 69) containing 
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codeine phosphate (9.0 mg/5ml) and ephedrine hydrochloride (7.2 mg/5ml), a mkture 
was prepared by mixing accurately 10 ml each of the codeine phosphate and ephedrine 
hydrochloride stock solutions and diluting to 25 ml in a calibrated flask, the resulting 
concentrations for both drugs in this mixture being 10.0 mg/5ml. Other mixtures with 
different compositions were prepared in the same way. 
2.2.5 Sample Pre-treatment 
No sample pre-treatment was necessary except for samples No. 7-9 (page 69-
70) containing high concentrations of the drugs and they were 5-fold diluted with O.IM 
sulphuric acid. 
2.2.6 Extraction Method 
10 ml of the cough-cold syrup or aqueous standard solution was pipetted into a 
100-ml separating funnel with addition of equal amount of 25 % V / V ammonia 
solution (Analar-grade, Merck). The drugs were extracted three times with 15-ml 
aliquots of chloroform. The organic layers were transferred to another separating funnel 
and washed with 5-6 ml of distilled water. The chloroform layer was collected into a 50-
ml V-flask via a funnel containing about 5 g of anhydrous sodium sulphate supported 
by a filter paper (No. 5A), The sodium sulphate on the filter was washed with small 
volumes of chloroform, and the washings were added to the filtrate, which was then 
diluted to mark with chloroform. 
2.2.7 Preparation of Working Internal Standard Solution 
An aliquot (10 ml) of the aqueous internal standard solution was treated as for 
the cough-cold syrups. 
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2.2.8 Simultaneous Determination of Active Ingredients in Cough-cold Syrups 
An aliquot (5 ml) of the sample solution and several aliquots (2-10 ml) of the 
standard solution after the extraction procedure described above were evaporated to 
dryness under a stream of nitrogen in a water bath at room temperature. Each residue 
was dissolved in exactly 1 ml of the working internal standard solution, 3 fi\ of which 
were injected into the chromatograph with a 10-/xl Hamilton syringe under the 
chromatographic conditions described above. The injections were performed in 
duplicate. 
The calibration graph was obtained by plotting the peak area ratios (drug to 
internal standard) against the concentrations of the drug in the injected standard 
solutions. 
The concentration of each drug in the injected sample solution was deduced 
from the respective calibration graph, and the amount of each drug in the original 
sample was then calculated. 
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2.3 RESULTS AND DISCUSSION 
2.3.1 Choice of Extraction Medium 
Because of the presence of dye(s), preservative(s), flavour(s) and a sweetening 
agent in most of the cough-cold syrups, the quantitative determination of the active 
ingredients in cough-cold mixtures become quite difficult. In order to analyse the active 
ingredients in cough-cold mixtures by gas chromatography, an efficient extraction 
method should be developed for separating the active ingredients from the other 
excipients. 
The drugs under study are reported to be extracted by organic solvents from 
alkaline media^^'"'^. Thus, the aqueous solutions of the drugs were first made alkaline 
with 25% V / V ammonia solution before extraction. Several common organic solvents, 
including chloroform, dichloromethane, diethylether and hexane, were selected for the 
evaluation of their suitability as the extraction medium. 
A n aqueous standard solution, containing chlorpheniramine maleate (0.4700 
mg/ml)，codeine phosphate (2.276 mg/ml), dextromethorphan hydrobromide (1.320 
mg/ml), ephedrine hydrochloride (1.542 mg/ml), and guaiphenesin (3.042 mg/ml), was 
prepared. Aliquots (2 ml) of the aqueous standard solution were made alkaline with 
ammonia solution and extracted once with exactly 20 ml of each solvent, and 10 ml of 
the organic layer was pipetted out and filtered after being dried with anhydrous sodium 
sulphate. The filtrate was evaporated to dryness under a stream of nitrogen, the residue 
was dissolved in exactly 1 ml of the working internal standard solution, and then 3.0 / i l 
of the final solution was injected onto the chromatograph. The peak area ratios (drug 
to internal standard) of each compound in various organic solvents are shown in Table 
2.3.1-1. 
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Since the peak area ratios so obtained were directly proportional to the amounts 
of drugs extracted from the aqueous to the organic phase, these ratios were used to 
compare the extraction capability of each solvent. The result shown in Table 2.3.1-1 
indicated that chloroform should be the best extraction medium while hexane was the 
poorest one. It is worthwhile to note that the extraction capability of chloroform was 
enhanced by the addition of 10% (V /V ) of methanol. Unfortunately, this mixed solvent 
also extracted the dyes in real samples. Therefore, methanol was not included in the 
subsequent experimental procedure, and chloroform was finally chosen to be the 
extraction medium. 
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Table 2.3.1-1 Peak area ratios^(individual drug to internal standard) after extraction with 
various solvents* 
Peak area ratios of the drugs in the mixture+ 
Extraction 
medium — 
1 2 3 4 5 
Chloroform 3.405 4.332 0.4452 2.777 3.823 
Dichloromethane 2.787 3.807 0.3307 2.421 3.791 
Diethylether 2.694 1.548 0.2285 2.229 2.870 
Hexane 1.055 n.d.” 0.3543 2.277 0.7384 
10% MeOH in CHCI3 3.436 4.724 0.4308 2.850 4.234 
•Chromatographic conditions as described in the Experimental section (section 2.2); 
+The drugs in the mixture, with concentration in the organic solvent in parentheses: 
(1) Ephedrine hydrochloride (1.542 mg/ml); 
(2) Guaiphenesin (3.042 mg/ml); 
(3) Chlorpheniramine maleate (0.4700 mg/ml); 
(4) Dextromethorphan hydrobromide (1.320 mg/ml); 
(5) Codeine phosphate (2.276 mg/ml). 
••No guaiphenesin signal was detected. 
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After choosing the extraction medium, the number of portions of chloroform 
used for extraction became the key point to determine the efficiency and simplicity of 
the proposed extraction method. Thus, the percentages extraction of each drug under 
study obtained by extraction with 3 x 15 ml and 5 x 15 ml of chloroform were deduced 
by U V spectrophotometric method with the following procedure: 
A standard solution of each drug was prepared by dissolving appropriate amount 
of the compound in O.IM sulphuric acid, 10 ml of which was pipetted into each of two 
lOO-ml separating funnels, namely I and II, and both were made alkaline with ammonia. 
The drug in separating funnels I and I I were extracted by three portions and five 
portions of 15 ml of chloroform, respectively. The organic layers in both separating 
funnels were dried with anhydrous sodium sulphate and filtered, and the filtrate and 
washings from I and I I were made up to 50-itlI and 100-ml, respectively, in calibrated 
flasks. From each of the calibrated flasks, portions of the solutions (5 ml from the 50-
ml V-flask and 10 ml from the 100-ml V-flask) were separately pipetted out and 
evaporated to dryness under a stream of nitrogen in a water bath. The residues were 
dissolved separately in 10 ml of O.IM sulphuric acid, and their U V absorbances at 
maximum absorbance wavelengths were measured. The amount of drug in each solution 
was deduced from the calibration graph. The percentage extraction of individual drug 
was then calculated. The results are shown in Table 2.3.1-2. 
By comparing the percentage extraction of individual drug obtained by 3 x 15 
ml and 5 x 15 ml extraction, no significant difference in the extraction efficiency was 
detected. As a result, three portions of 15 ml of chloroform were used in the proposed 
extraction method in order to save time and reagent. 
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Table 2.3.1-2 Percentage extraction of individual drug obtained by 3 x 15 ml and 5 x 15 
ml extraction. 
Compound Concentration Percentage extraction (%) 
in aqueous 
solution 
(mg/ml) By 3 X 15 ml By 5 x 15 ml 
extraction extraction 
Bromhexine HCl 0.5520 99.2 100.2 
Chlorpheniramine 1.028 97.4 98.1 
maleate 
Codeine phosphate 1.152 95.3 96.3 
Dextromethorphan 1.028 100.1 98.6 
HBr 
Diphenhydramine 2.008 97.1 99 5 
HCl 
Ephedrine HCl 3.004 95.1 96.4 
Guaiphenesin 1.352 90.3 90.5 
Papaverine HCl 0.7560 99.3 100.1 
Pseudoephedrine 2.992 99.0 99.1 
HCl 
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2.3.2 Choice of Stationary Phase 
As it was intended to resolve a large number of drugs using the proposed 
method, the proper choice of stationary phase was also important. Since there was no 
perfect guidelines for choosing the best stationary phase, the optimal separation 
conditions could only be realized by trial-and-error experiments. A number of stationary 
phases on Supelcoport (80/100 mesh), including 3% OV-1, 3% OV-17, 3% OV-25 and 
3% OV-225, were assessed. The composition, McReynolds constants, and temperature 
limits of these stationary phases are shown in Table 2.3.2-1. A l l of them can tolerate 
high column temperatures (i.e. maximum temperature limits are high), thus, they are 
suitable for separation of non-volatile drugs of interest. The large difference in 
McReynolds constants of the various stationary phases indicated that each of them 
should have different separation power for the drugs under study. 
During the study, the flow rate of nitrogen was set at 30 ml/min., which was 
commonly used for the determination of drugs. The optimum temperature programming 
conditions for separating the drugs under study were found for each column. The 
retention time and peak shapes of the drugs under the optimised conditions for each 
column are listed in Table 2.3.2-2. The typical chromatograms of the drugs obtained 
by the various columns are shown in Figure 2.3.2-1 to Figure 2.3.2-4. It is noted that 
only ephedrine but not pseudoephedrine is shown as these two compounds are 
stereoisomers and have the same peak shape and retention time. They have similar 
properties and will never co-exist in cough-cold syrups. 
Both stationary phases of 3% OV-1 and 3% OV-225 were found to be not 
suitable for the separation of all eight ingredients. The former gave an overlapping 
peak of bromhexine HCl and codeine phosphate, while, the latter could not completely 
resolve the peaks of chlorpheniramine maleate and diphenhydramine HCl. Although 
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the stationary phase of 3% OV-17 could separate all of the drugs under study, the 
overall running time was rather long and the resolution was not good enough. In terms 
of good peak shapes, resolution, and overall running time, the column packed with 3% 
OV-25 was found to be the most satisfactory one. 
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Table 2.3.2-1 The specifications of various stationary phases*. 
Phase Composition Temperature McReynolds constants** 
limit (OQ ； 
Min./Max. X， Y， Z’ U， S， 
OV-1 Dimethyl 100/350 16 55 44 65 42 
(gum) 
OV-17 Phenyl methyl, 0/375 119 158 162 243 202 
50% phenyl 
OV-25 Phenyl methyl 0/350 178 204 208 305 280 
diphenyl, 
75% phenyl 
OV-225 Cyanopropylmethyl 0/265 228 369 338 492 386 
-phenyl methyl 
•Reference : SUPELCO, International Catalog 25, 1987, pp.88. 
**Test solutes : X' 二 benzene; 
Y，二 1-butanol; 
Z，= methyl-n-propyl ketone; 
U' = nitromethane; and 
S’ = pyridine. 
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Table 2.3.2-2 The retention times and peak shapes of the drugs under study in various 
types of column under the conditions specified in Table 2.3.2-2a. 
Retention time*, min. 
Glass column packed with 
Compounds 3% OV-1 3% OV-17 3% OV-25 3% OV-225 
Ephedrine H Q ” 
Pseudoephedrine HCl 1.06 (s) 1.18 (s) 1.04 (s) 2.80 (s) 
Guaiphenesin 2.87 (s) 4.59 (s) 3.67 (st) 7.30 (s) 
Diphenhydramine HCl 4.94 (s) 6.12 (st) 4.88 (s) 9.46 (so) 
Chlorpheniramine 
maleate 6.42 (s) 7.95 (st) 6.22 (s) 9.70 (so) 
Dextromethorphan HBr 7.79 (s) 9.51 (st) 7.49 (s) 11.12 (s) 
Bromhexine HCl 10.31 (o) 11.99 (s) 9.37 (s) 15.52 (s) 
Codeine phosphate 10.31 (o) 13.27 (s) 10.84 (s) 20.01 (s) 
Papaverine HCl 14.73 (s) 2231 (s) 19.14 (s) 30.59 (b) 
Description of the peak shape was enclosed in parentheses: 
b，board; o，overlapped; s，sharp; so, sharp but overlapped; and st, sharp with tailing. 
•• Ephedrine HCl and pseudoephedrine HCl had the same retention time and peak 
shape in each type of column. 
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Table 2.3.2-2a Optimised chromatographic conditions for columns in Table 2.3.2-
2. The columns (5 ft. x 2 mm i.d.) were packed respectively with 
the following stationary phases on Supelcoport (80/100 mesh). 
stationary phase 
3% OV-1 3% OV-17 3% OV-25 3% OV-225 
Initial temperature 150 160 170 180 
(°C) (1 min.) (1 min. ) (1 min.) (1 min.) 
Heating rate 8 8 10 6 
(°C/inin.) 
Final temperature 260 260 265 258 
(°C) (2 min.) (10 min.) (10 min.) (18 min.) 
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Figure 2.3.2-1 Gas chromatogram of the drugs of interest obtained by a column of 3% 
OV-1 under the optimised conditions. A, solvent; B, ephedrine 
hydrochloride (2.98 mg/ml); C, guaiphenesin (5.95 mg/ml); D, 
diphenhydramine hydrochloride (2.50 mg/ml); E, chlorpheniramine 
maleate (3.03 mg/ml); F, dextromethorphan hydrobromide (1.93 
mg/ml); G, bromhexine hydrochloride (1.96 mg/ml) and codeine 
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Figure 2.3.2-2 Gas chromatogram of the drugs of interest obtained by a column of 3% 
OV-17 under the optimised conditions. A, solvent; B，ephedrine 
hydrochloride (2.98 mg/ml); C, guaiphenesin (5.95 mg/ml); D， 
diphenhydramine hydrochloride (2.50 mg/ml) ; E, chlorpheniramine 
maleate (3.03 mg/ml); F, dextromethorphan hydrobromide (1.93 
mg/ml); G, bromhexine hydrochloride (1.96 mg/ml), H, codeine 
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Figure 2.3.2-3 Gas chromatogram of the drugs of interest obtained by a column of 3% 
OV-25 under the optimised conditions. A, solvent; B, ephedrine 
hydrochloride (0.87 mg/ml); C, guaiphenesin (1.54 mg/ml); D, 
diphenhydramine hydrochloride (1.09 mg/ml); E, chlorpheniramine 
maleate (0.90 mg/ml); F, dextromethorphan hydrobromide (1.00 
mg/ml); G, bromhexine hydrochloride (0.77 mg/ml); H, clomipramine 
hydrochloride (0.30 mg/ml); I，codeine phosphate (0.91 mg/ml); and J, 
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Figure 2.3.2-4 Gas chromatograms of the drugs of interest obtained by a column of 3% 
OV-225 under the optimised conditions. A, solvent; B，ephedrine 
hydrochloride (2.98 mg/ml); C, guaiphenesin (5.95 mg/ml) ; D, 
diphenhydramine hydrochloride (2.50 mg/ml); E，chlorpheniramine 
maleate (3.03 mg/ml); F, dextromethorphan hydrobromide (1.93 
mg/ml) ; G, bromhexine hydrochloride (1.96 mg/ml), H, codeine 
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2.3.3 Optimization of The Instrumental Parameters 
In gas chromatography, there are several instrumental parameters needed to be 
optimised, including the flow rate of carrier gas, flow rates of hydrogen and air for the 
F ID detector, and temperature programming conditions. The flow rate of carrier gas, 
nitrogen, was chosen to be 30 ml/min., which was not uncommon in analysis of drugs. 
The flow rates of hydrogen and air were suggested to be 30 and 300 ml /m in ” 
• 13 
respectively • The optimization of temperature programming conditions is so important 
because it may affect the overall running time, resolution of the peaks, and sensitivities 
of the signals. 
In the previous section，the rough temperature programming conditions for 
various columns were found by observing the resolution of the peaks and overall running 
times of the chromatograms. After choosing the best stationary phase, the temperature 
programming conditions were then optimised. 
A n aqueous standard solution containing known amounts of bromhexine 
hydrochloride, chlorpheniramine maleate, codeine phosphate, dextromethorphan 
hydrobromide, diphenhydramine hydrochloride, ephedrine hydrochloride, guaiphenesin, 
and papaverine hydrochloride was prepared. An aliquot (10 ml) of the aqueous standard 
solution was extracted into chloroform by the procedure mentioned in the Experimental 
section, and a series of standard solution for injection was then prepared. The final 
temperature of the temperature programming was chosen to be 265 °C because a 
higher temperature could shorten the life of the column while a lower temperature 
would lengthen the overall running time. By fixing the heating rate and final 
temperature of the temperature programming, the initial temperature was optimised. 
For each initial temperature, calibration graph of each drug was obtained, and the 
results are listed in Table 2.3.3-1. It was found that the slopes of the calibration graphs 
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(or the sensitivities) for the drugs slightly increased with increasing the initial 
temperature. However, the peak of ephedrine (or pseudoephedrine) was very close to 
the solvent peak at an initial temperature of 190 °C. Finally, an initial temperature of 
170 °C was chosen, which offered a better sensitivity for each drug. 
After choosing the initial temperature, the heating rate was adjusted. By fixing 
the initial and final temperature of the temperature programming, retention times of 
the drugs at various heating rates were obtained. The results are shown in Table 2.3.3-
2. The overall running time decreased with increasing the heating rate. However, the 
faster the heating rate, the poorer was the resolution of the peaks. In order to have a 
faster running time and better resolution of the peaks, a heating rate of 10 °C/niin. was 
selected. 
In order to test the performance (or reproducibility) of the optimised 
temperature programming, a chloroform solution containing all the drugs under study 
was prepared and injected ten times onto the column under the optimised 
chromatographic conditions, and the relative standard deviation of the peak area ratios 
for each drug was then calculated. The results are shown in Table 2.3.3-3. The relative 
standard deviation of each drug ranged from 0.49 to 4.7%, indicating that the 
reproducibility of the optimised temperature programming was good enough. 
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Table 2.3.3-1 The slopes of the calibration graphs of the drugs at various initial 
temperatures but with fixed heating rate and final temperature of the 
temperature programming 
Slopes of the calibration graphs, ml /mg 
Compounds 
Initial temperature*, °C 
150 170 190 
Bromhexine HCl 2.137 2.139 2.210 
Chlorpheniramine 
maleate 2.358 2.544 2.566 
Codeine phosphate 2.149 2.188 2.237 
Dextromethorphan HBr 3.098 3.177 2.998 
Diphenhydramine HCl 3.439 3.576 3.929 
Ephedrine HCl 2.428 2.953 n.d；* 
Guaiphenesin 1.929 1.994 2.215 
Papaverine HCl 2.926 3.125 3.169 
+The heating rate was set at 10 °C/niin.; and the final temperature was set at 265 °C 
and kept for 10 min. 
•The initial temperature was kept for 1 min. 
••The peak of ephedrine was too close to the solvent peak and therefore no calibration 
graph was plotted. 
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Table 2.3.3-2 Retention times of the drugs at various heating rates but with fixed initial 
and final temperatures for the temperature programming 
Retention times, min. 
Compounds 
Heating rate, °C/min. 
8 10 12 
Ephedrine HCl 1.06 1.05 1.05 
Guaiphenesin 3.79 3.64 3.54 
Diphenhydramine HCl 5.15 4.90 4.62 
Chlorpheniramine maleate 6.70 6.24 5.80 
Dextromethorphan HBr 8.21 7.52 6.90 
Bromhexine HCl 10.48 9.37 8.50 
Codeine phosphate 12.26 10.85 9.76 
Papaverine HCl 20.80 19.12 17.82 
+The initial temperature was set at 170 °C and kept for 1 min.; and the final 
temperature was set at 265 and kept for 10 min. 
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Table 2.3.3-3 Data for testing the reproducibility of the optimised temperature 
programming. 
Drug Concentration Relative standard 
mg/ml deviation* 
(%) 
Bromhexine HCl 0.7720 0.73 
Chlorpheniramine 0.9160 1.3 
maleate 
Codeine phosphate 0.9120 2.0 
Dextromethorphan HBr 1.004 0.49 
Diphenhydramine HCl 1.092 1.3 
Ephedrine HCl 0.8680 4.7 
Guaiphenesin 1.536 3.4 
Papaverine HCl 0.4680 3.3 
Pseudoephedrine HCl 1.250 1.7 
•For ten replicate injections. 
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2.3.4 Preparation of The Calibration Graphs 
The calibration graph of each drug under study was obtained by plotting the 
peak area ratios (drug to internal standard) against the corresponding injection 
concentrations. In quantitative determination of the drugs in real samples, results were 
deduced from the respective calibration graph for each drug with the help of the linear 
regression equation. 
2.3.4.1 Calibration graph of bromhexine hydrochloride 
A n aqueous standard solution of bromhexine hydrochloride (0.3016 mg/ml) was 
prepared by dissolving appropriate amount of the drug in 50 ml of sulphuric acid (0.1 
M) in a calibrated flask. 10 ml of the aqueous standard solution was made alkaline 
with ammonia solution and extracted with chloroform (3 x 15 ml), detailed procedure 
being found in the Experimental section. The organic layer (chloroform) was filtered 
after being dried with anhydrous sodium sulphate, and the filtrate was made up to 50 
ml with chloroform in a calibrated flasks (Solution I). 15.00, 12.50, 10.00，8.00，6.00， 
4.00, 2.00，and 1.00 ml of Solution I were pipetted separately into a series of V-flasks 
and evaporated to dryness under nitrogen in a water bath at room temperature. The 
residue was completely dissolved in exactly 1 ml of the internal standard solution 
(Solution II)，3.0 lA of which was injected onto the chromatograph under the 
chromatographic conditions described in the Experimental section. A l l injection was 
performed in duplicate. The calibration graph was obtained by plotting the peak area 
ratios (drug to internal standard) against concentrations of Solution 11. The data of 
the calibration graph are listed in Table 2.3.4.1-1, and the calibration graph is shown 
in Figure 2.3.4.1-1. 
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Table 2.3.4.1-1 Data for the calibration graph of bromhexine hydrochloride. 
Concentration of bromhexine Mean peak area ratio 









Linear working range = 0.06 - 0.90 mg/ml; 
Slope 二 2.661 ml/mg; 
Intercept = -0.03312; 
Correlation coefficient = 0.9999; and 
Detectable amount 
per injection 二 0.18 /ig. 
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Figure 2.3.4.1-1 Calibration graph of bromhexine hydrochloride. 
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2.3.4.2 Calibration graph of chlorpheniramine maleate 
The calibration graph of chlorpheniramine maleate was prepared using an 
aqueous standard solution of chlorpheniramine maleate (0.3008 mg/ml) and following 
the procedure for bromhexine hydrochloride. The data of the calibration graph are 
listed in Table 2.3.4.2-1，and the calibration graph is shown in Figure 2.3.4.2-1. 
Table 2.3.4.2-1 Data for the calibration graph of chlorpheniramine maleate. 
Concentration of Mean peak area ratio 









Linear working range 二 0.06 - 0.90 mg/ml; 
Slope = 2.654 ml/mg; 
Intercept = -0.1076; 
Correlation coefficient 二 0.9997; and 
Detectable amount 
per injection 二 0.18 f i g . 
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Figure 2.3.4.2-1 Calibration graph of chlorpheniramine maleate. 
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2.3.4.3 Calibration graph of codeine phosphate 
The calibration graph of codeine phosphate was prepared using an aqueous 
standard solution of codeine phosphate (0.5128 mg/ml) and following the procedure 
for bromhexine hydrochloride. The data of the calibration graph are listed in Table 
2.3.4.3-1，and the calibration graph is shown in Figure 2.3.4.3-1. 
Table 2.3.4.3-1 Data for the calibration graph of codeine phosphate. 
Concentration of Mean peak area ratio 









Linear working range 二 0.10 - 1.54 mg/ml; 
Slope 二 2.810 ml/mg; 
Intercept = -0.1312; 
Correlation coefficient = 0.9999; and 
Detectable amount 
per injection 二 0.18 fig. 
46 








i I 1 I q o 
… 寸 ra rH o OpBJ BaiB 47 
2.3.4.4 Calibration graph of dextromethorphan hydrobromide 
The calibration graph of dextromethorphan hydrobromide was prepared using 
an aqueous standard solution of dextromethorphan hydrobromide (0.5056 mg/ml) and 
following the procedure for bromhexine hydrochloride. The data of the calibration graph 
are listed in Table 2.3.4.4-1, and the calibration graph is shown in Figure 2.3.4.4-1. 
Table 2.3.4.4-1 Data for the calibration graph of dextromethorphan hydrobromide. 
Concentration of Mean peak area ratio 









Linear working range = 0.20 - 1.52 mg/ml; 
Slope = 3.474 ml/mg; 
Intercept = -0.3337; 
Correlation coefficient = 0.9999; and 
Detectable amount 
per injection 二 0.18 fig. 
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2.3.4.5 Calibration graph of diphenhydramine hydrochloride 
The calibration graph of diphenhydramine hydrochloride was prepared using an 
aqueous standard solution of diphenhydramine hydrochloride (0.5248 mg/ml) and 
following the procedure for bromhexine hydrochloride. The data of the calibration graph 
are listed in Table 2.3.4.5-1, and the calibration graph is shown in Figure 2.3.4.5-1. 
Table 2.3.4.5-1 Data for the calibration graph of diphenhydramine hydrochloride. 
Concentration of Mean peak area ratio 









Linear working range 二 0.20 - 1.58 mg/ml; 
Slope 二 4.316 ml/mg; 
Intercept = -0.3963; 
Correlation coefficient = 0.9999; and 
Detectable amount 
per injection 二 0.18 fig. 
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2.3.4.6 Calibration graph of ephedrine hydrochloride 
The calibration graph of ephedrine hydrochloride was prepared using an aqueous 
standard solution of ephedrine hydrochloride (0.5120 mg/ml) and following the 
procedure for bromhexine hydrochloride. The data of the calibration graph are listed in 
Table 2.3.4.6-1，and the calibration graph is shown in Figure 2.3.4.6-1. The calibration 
graph exhibited a large negative intercept and showed a working range between 0.4 and 
1.54 mg/ml. There was no detectable signal of ephedrine at a concentration below 0.4 
mg/ml. In comparison with other drugs under study, ephedrine was a volatile compound, 
and part of it would probably be lost during evaporation under nitrogen. The loss of 
ephedrine in evaporation became significant at low concentration of the compound, and 
hence, no signal was detected at a concentration below 0.4 mg/ml. 
52 
Table 2.3.4.6-1 Data for the calibration graph of ephedrine hydrochloride. 
Concentration of Mean peak area ratio 







Linear working range 二 0.40 - L54 mg/ml; 
Slope = 3.098 ml/mg; 
Intercept = -1.172; 
Correlation coefficient = 0.99992; and 
Detectable amount 
per injection = 1.20 jig. 
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2.3.4.7 Calibration graph of guaiphenesin 
The calibration graph of guaiphenesin was prepared using an aqueous standard 
solution of guaiphenesin (1.795 mg/ml) and following the procedure for bromhexine 
hydrochloride. The data of the calibration graph are listed in Table 2.3.4.7-1，and the 
calibration graph is shown in Figure 2.3.4.7-1. 
Table 2.3.4.7-1 Data for the calibration graph of guaiphenesin. 
Concentration of Mean peak area ratio 









Linear working range = 0.35 - 5.38 mg/ml; 
Slope 二 2.911 ml/mg; 
Intercept 二 -0.6736; 
Correlation coefficient = 0.9998; and 
Detectable amount 
per injection 二 0.18 fig. 
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Figure 2.3.4.7-1 Calibration graph of guaiphenesin. 
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Figure 2.3.4.9-1 Calibration graph of pseudoephedrine hydrochloride. 
The calibration graph of papaverine hydrochloride was prepared using an 
aqueous standard solution of papaverine hydrochloride (0.1576 mg/ml) and following 
the procedure for bromhexine hydrochloride. The data of the calibration graph are 
shown in Table 2.3.4.8-1, and the calibration graph is shown in Figure 2.3.4.8-1。 
Table 2.3.4.8-1 Data for the calibration graph of papaverine hydrochloride. 
Concentration of Mean peak area ratio 









Linear working range = 0.03 - 0.48 mg/ml; 
Slope = 3.223 ml/mg; 
Intercept 二 -0.04843; 
Correlation coefficient = 0.9998; and 
Detectable amount 
per injection 二 0.18 fig. 
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Figure 2.3.4.8-1 Calibration graph of papaverine hydrochloride. 
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Figure 2.3.4.9-1 Calibration graph of pseudoephedrine hydrochloride. 
The calibration graph of pseudoephedrine hydrochloride was prepared using an 
aqueous standard solution of pseudoephedrine hydrochloride (0.6240 mg/ml) and 
following the procedure for bromhexine hydrochloride. The data of the calibration graph 
are listed in Table 2.3.4.9-1, and the calibration graph is shown in Figure 2.3.4.9-1. The 
calibration graph of pseudoephedrine was similar to that of ephedrine, which also 
showed a large negative intercept. In fact, no signal of pseudoephedrine was detected 
at a concentration below 0.49 mg/ml. Same as ephedrine, the absence of signals of 
pseudoephedrine at low concentration might be due to the loss of the compound during 
evaporation under nitrogen. 
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Table 2.3.4.9-1 Data for the calibration graph of pseudoephedrine hydrochloride. 
Concentration of Mean peak area ratio 








Linear working range 二 0.50 - 1.87 mg/ml; 
Slope = 2.790 ml/mg; 
Intercept 二 -0.8799; 
Correlation coefficient = 0.9999; and 
Detectable amount 
per injection = 1.50 Mg. 
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2.3.5 Recovery Test and Precision 
In order to test the reliability of the proposed method, recovery tests were 
performed by adding known amount of each drug to a cough-cold syrup where it was 
known to be absent. For each drug, four replicate determinations were made. 
As an example, the recovery tests of bromhexine hydrochloride, guaiphenesin 
and pseudoephedrine hydrochloride were performed with the following procedure: 
An aqueous standard solution with known amounts of bromhexine hydrochloride 
(1.508 mg/ml), guaiphenesin (8.972 mg/ml) and pseudoephedrine hydrochloride (3.120 
mg/ml) was prepared. 10 ml of the standard solution was pipetted into a 25-ml V-
flask and diluted to mark with a cough-cold syrup where bromhexine hydrochloride, 
guaiphenesin and pseudoephedrine hydrochloride were absent (Sample I). The amounts 
of the added drugs in Sample I were determined using the proposed method as 
described in the Experimental section. The recovery of each drug was then calculated. 
The recovery tests of other drugs under study were performed in a similar manner. The 
results are present in Table 2.3.5-1. The mean results of four analyses for each drug 
ranged from 96.0 to 99.7%, which can be considered to be good recoveries. 
The precision of the proposed method was checked by calculating the relative 
standard deviation for the above determinations, and the results are also shown in Table 
2.3.5-1. The relative standard deviation of four analyses for each drug under study 
ranged from 0.52 to 1.77%. 
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Table 2.3.5-1 Results of the recovery tests and precision for the drugs under study using 
the proposed method. 
Drug Amount added Recovery* Mean recovery Relative standard 
(mg/5 ml) (%) (%) deviation (%) 
Bromhexine HCl 3.016 95.43 
95.78 
96.78 96.2 0.59 
96.63 
Chlorpheniramine 3.008 98.10 
maleate 99.60 
96.32 97.9 1.21 
97.43 
Codeine phosphate 5.015 99.69 
99.68 
101.5 99.7 1.21 
98.09 
Dextromethorphan 5.080 96.19 
HBr 96.72 
95.81 96.0 0.52 
95.37 
Diphenhydramine 5.250 99.66 
HCl 97.32 
100.1 98.8 1.15 
98.04 
Ephedrine HCl 5.040 98.00 
99.10 
96.61 97.8 0.93 
97.39 
Guaiphenesin 17.95 98.77 
99.72 
96.19 98.1 1.33 
97.80 
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cont'd Table 2.3.6-1. 
Drug Amount added Recovery* Mean recovery Relative standard 
(mg/5 ml) (%) (%) deviation (%) 
Papaverine HCl 1.680 94.51 
98.21 
96.66 97.0 1.62 
98.45 
Pseudoephedrine 6.24 95.94 
HCl 98.68 
95.64 97.5 1.77 
99.64 
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2.3.6 Determination of active ingredients in cough-cold syrups 
The contents of the drugs under study in nine commercially available cough-cold 
syrups were determined in triplicate using the proposed method. The samples under 
study contained combinations of several active ingredients, which were identified by 
comparing the retention time of the peaks observed with those obtained from standard 
solutions containing the respective active ingredients examined under the same 
conditions. The results obtained were compared with those obtained using an established 
HPLC method^ and with the corresponding label values. A brief description of the 
samples is shown in Table 2.3.6-1，and the results of the sample analysis are present 
in Table 2.3.6-2. Typical chromatograms for sample No.l and No.9 are shown in Figure 
2.3.6-1 and Figure 2.3.6-2, respectively, where no extra peaks due to other excipients are 
evident. 
From Table 2.3.6-1, it can be seen that the results obtained with the proposed 
method were in good agreement with those obtained using the counter-check HPLC 
method and with the respective label values. 
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Table 2.3.6-1 Brief description of the samples. 
Batch Name Source Ingredients Labelled 
No. amount 
(mg/5ml) 
1 DECOXINE Commercially Bromhexine HCl 2.5 
Cough Syrup available Codeine phosphate 4.5 
Diphenhydramine HCl 4.5 
Ephedrine HCl 4.5 
Papaverine HCl 1.25 
2 COLDREX Commercially Chlorpheniramine 1.0 
Cough Syrup available maleate 
Dextromethorphan HBr 5.0 
Guaiphenesin 25.0 
Phenylephrine HCl 5.0 
3 BREACOL Commercially Chlorpheniramine 1.0 
Cough Syrup available maleate 
Dextromethorphan HBr 5.0 
Guaiphenesin 25.0 
Menthol 5.0 
Phenylephrine HCl 5.0 
4 P.E.C. Universal Codeine phosphate 9.0 
Syrup Pharmaceutical Ephedrine HCl 7.2 
Laboratories, Promethazine HCl 3.6 
Ltd., H.K. Flavoured vehicle q.s. 
5 UNI-VASIN Universal Chlorpheniramine 4.0 
L IQUID Pharmaceutical maleate 
Laboratories, Phenylephrine HCl 5.0 
Ltd., H.K. Phenylpropanolamine 5.0 
HCl 
Flavoured vehicle q.s. 
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cont'd Table 2.3.6-1. 
Batch Name Source Ingredients Labelled 
No. amount 
(mg/5ml) 
6 WANI Wah Ning Ammonium chloride 110 
Cough Syrup Dispensary Chlorpheniramine 2.0 
Ltd. maleate 
Codeine phosphate 10.0 
Ephedrine HCl 5.0 
Flavoured syrup q.s. 
7 ROBITUSSIN Commercially Guaiphenesin 100.0 
Cough Syrup available Alcohol 3.5% 
8 SUDAFED Commercially Guaiphenesin 100.0 
Expectorant available Pseudoephedrine HCl 30.0 
9 ROBITUSSIN Commercially Guaiphenesin 100.0 
Expectorant available Pseudoephedrine HCl 30.0 
Alcohol 1.4% 
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Table 2.3.6-2 The assay results for the determination of various active ingredients in 
cough-cold syrups. 
Percentage of label claim 
Batch Ingredients Labelled 
No. values By proposed method 
(mg/Sml) By HPLC 
amount method 
found mean* 
1 Bromhexine HCl 2.5 92.4 
92.4 92.5 (0.2) 95.2 
92.8 
Codeine phosphate 4.5 101.3 
101.3 101.5 (0.2) 103.8 
101.8 
Diphenhydramine 4.5 104.2 
HCl 104.0 104.4 (0.4) 96.2 
104.9 
Ephedrine HCl 4.5 101.1 
100.0 101.4 (1.3) 97.1 
103.1 
Papaverine HCl 1.25 85.6 
92.8 90.9 (3.8) 90.4 
94.4 
2 Chlorpheniramine 1.0 96.0 
maleate 90.0 93.7 (2.6) 93.0 
95.0 
Dextromethorphan 5.0 94.8 
HBr 95.6 95.3 (03) 99.4 
94.8 
Guaiphenesin 25.0 96.0 
98.5 96.5 (1.5) 91.6 
95.0 
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cont'd Table 2.3.6-1. 
Percentage of label claim 
Batch Ingredients Labelled 
No. values By proposed method 
(mg/5ml) By HPLC 
amount 女 method 
found mean* 
3 Chlorpheniramine 1.0 89.2 
maleate 87.3 88.3 (0.8) 93.0 
88.5 
Dextromethorphan 5.0 94.8 
HBr 95.2 95.1 (0.2) 100.6 
95.2 
Guaiphenesin 25.0 99.5 
99.4 98.5 (1.3) 96.4 
96.7 
4 Codeine phosphate 9.0 100.0 
99.2 99.6 (0.3) 102.8 
99.4 
Ephedrine HCl 7.2 96.2 
94.4 94.8 (1.0) 97.9 
93.8 
5 Chlorpheniramine 4.0 96.9 
maleate 98.1 97.0 (0.9) 102.8 
95.9 
6 Chlorpheniramine 2.0 83.5 
maleate 85.0 84.4 (0.7) 85.5 
84.8 
Codeine phosphate 10.0 86.0 
92.5 90.6 (3.3) 88.5 
93.3 
Ephedrine HCl 7.2 86.0 
94.0 90.0 (3.3) 89.0 
90.0 
7 Guaiphenesin 100.0 101.3 
104.1 103.1 (1.3) 102.5 
103.8 
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cont'd Table 2.3.6-1. 
Percentage of label claim 
Batch Ingredients Labelled 
No. values By proposed method 
(mg/Sml) By HPLC 
amount • method 
found mean* 
8 Guaiphenesin 100.0 113.3 
111.7 111.4 (1.7) 115.3 
109.2 
Pseudoephedrine 30.0 107.8 
HCl 104.4 107.8 (2.7) 111.9 
111.1 
9 Guaiphenesin 100.0 97.4 
96.6 97.3 (0.5) 99.4 
97.9 
Pseudoephedrine 30.0 100.9 
HCl 106.1 102.3 (2.7) 105.6 
99.9 
•Standard deviation is enclosed in parentheses. 
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Figure 2.3.6-1 The chromatogram of sample No.l, with peaks of A, ephedrine 
hydrochloride; B, diphenhydramine hydrochloride; C, bromhexine 
hydrochloride; D, clomipramine hydrochloride; E, codeine phosphate; 
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Figure 2.3.6-2 The chromatogram of sample No.9, with peaks of A, pseudoephedrine 
hydrochloride; B, guaiphenesin; and C, clomipramine hydrochloride. 
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A simple, efficient, and accurate gas-liquid chromatographic method for the 
simultaneous determination of bromhexine, chlorpheniramine, codeine, 
dextromethorphan, diphenhydramine, ephedrine (or pseudoephedrine), guaiphenesin, 
and papaverine in cough-cold syrups has been developed. The proposed method 
involved a preliminary extraction with chloroform under alkaline conditions, which has 
been shown to be successful to extract the basic drugs from the sample matrices so that 
the interferences due to other excipients, such as dyes, flavours, and preservative present 
in samples, can be minimised. The time for running a chromatogram for the syrups was 
10 min. or less when papaverine was absent, and about 20 min. when the latter was 
present. The method has been applied successfully and conveniently to the 
determination of the drugs mentioned above, individually or together, in nine 
commercial cough-cold syrups. The method is also suitable as a stability indicating assay. 
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CHAPTER 3 
GAS-LIQUID CHROMATOGRAPHIC DETERMINATION 
OF ATROPINE SULFATE/HYOSCYAMINE SULFATE， 
HOMATROPINE HYDROBROMIDE AND HYOSCINE 
HYDROBROMIDE IN PHARMACEUTICAL 
PREPARATIONS 
3.1 INTRODUCTION 
Atropine, homatropine, hyoscine (or scopolamine) and hyoscyamine are alkaloids 
have similar structures and properties. They are widely used in pharmaceutical 
preparations, such as eye drops, injections, and tablets, with quantities ranging from 
micrograms to milligrams. The actions and uses of these alkaloids are illustrated as 
follows1-3: 
i. Atropine and hyoscyamine 
Structure of atropine sulfate: 










. CH,OH J, 
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Atropine is a mkture of (±)-hyoscyamine, prepared by racemisation of 
(-)-hyoscyamine, and thus, both atropine and hyoscyamine have the same properties. 
Atropine has central and peripheral actions. It first stimulates and then depresses the 
central nervous system and has antispasmodic actions on smooth muscle and reduces 
secretions, especially salivary and bronchial secretions. It also dilates the pupil, paralyses 
the muscles of accommodation, and increases intra-ocular pressure. In addition, as it 
diminishes gastric and intestinal motility, it is also used in the treatment of gastric and 
duodenal ulcer. 
ii. Homatropine 





Homatropine has actions similar to those described under atropine. It is less 
potent than atropine and is rarely used internally, and its chief use is in ophthalmology 
to dilate the pupil. It produces mydriasis more rapidly than atropine, but its effect 
persists for a shorter time, and may be readily terminated by the action of 
physostigmine. It has less tendency than atropine to increase the intra-ocular pressure. 
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iii. Hyoscine (or Scopolamine) 
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Hyoscine has peripheral and central actions. Same as atropine, it antagonises 
the muscarinic effects of acetylcholine. It produces mydriasis and relaxes accommodation 
more quickly but for a shorter time than atropine. 
Numerous methods have been developed for the quantitative determination of 
these alkaloids mentioned, including derivative spectrophotometry"^, fluorometry^'®, high 
performance liquid chromatography^'®, gas-liquid chromatography®"''\ potentiometric 
titration^ and spectrophotometry^^. However, few of them could simultaneously 
determine all of the alkaloids under study. The spectrophotometric method required 
large sample size because of the low U V absorptivities of the alkaloids and also the low 
level of the alkaloids in pharmaceutical preparations. Fluorometric detectors were used 
in some HPLC methods^'^ for trace analysis, however, many laboratories cannot afford 
the high costs of these equipments. The BP potentiometric titration method^ lacks 
selectivity in the determination of the alkaloids. None of the GC methods are 
applicable for simultaneous analysis of all the alkaloids mentioned above. Although the 
USP method” used gas chromatography for the quantitative assay of the alkaloids, the 
method used homatropine HBr as the internal standard, and hence, its use was 
restricted to atropine, hyoscine and hyoscyamine only. Besides, this official method 
required a cumbersome preliminary extraction process. 
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The object of the present work was to develop a simple and efficient gas-liquid 
chromatographic method for the determination of the three* alkaloids, individually or 
together, in various pharmaceutical preparations. The extraction and chromatographic 
conditions for the analysis of these alkaloids under study were optimised. The proposed 
method had been applied to determine the contents of the alkaloids in seven 
commercially available pharmaceutical preparations. The results obtained by the 
proposed method were compared with those obtained using an established HPLC 
method^ and the label claimed values. 
Since atropine is prepared by racemisation of (-)-hyoscyamine, both have the same 
properties and chromatographic behaviours, i.e. same peak shape and retention time. 






A Varian Model 3700 Gas Chromatograph equipped with a flame ionization 
detector, and attached to a Hitachi 833A Data Processor was used. 
3.2.1.2 Gas chromatographic conditions 
A glass column (5ft. x 2 mm i.d.) was packed with 3% OV-225 on Supelcoport 
(80/100 mesh). The carrier gas was nitrogen with a flow rate of 30 ml/min. The flow 
rate of hydrogen and air were 30 and 300 ml/min., respectively. The injection port and 
detector temperatures were kept at 260 and 250 °C, respectively. The initial column 
temperature was kept at 220 °C for the first minute, then programmed to a final 
temperature of 260 °C at a heating rate of 15 °C/min.，and then maintained at this 
temperature for 4 min. and 2 min.，respectively, for samples with and without hyoscine. 
The attenuation was 1 in the gas chromatograph and varied in the data processor (8-10, 
depending on the concentration of the injected solution). The chart speed of the data 
processor was 2.5 mm/min.. When not in use, the column was kept at 50 °C with a 
nitrogen flow rate of 30 ml/min. While broadening of the peaks was observed, which 
was an indication of decomposition of the packing material, the first few inches of the 
packing material near the injection port was replaced, and the column could be used for 
about six months. 
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3.2.2 The Counter-check HPLC Method 
The results obtained using the proposed method were compared with an 
established HPLC method?. In performing the counter-check method, the procedure of 
the original method was followed except that the reagent 20% tetramethylammonium 
hydroxide in methanol was replaced by 25% tetraethylammonium hydroxide in methanol 
since the former reagent was not available in our laboratory. 
3.2.2.1 Instrumentation 
The liquid chromatograph consisted of a controller (Beckman, model 421A), a 
solvent pump (Beckman, model HOB), an injection system (Altex, 210 valve), an 
analytical column ALLTECH, Applied Science Labs, 5 /x Econosphere C18 Cartridge 
250 X 4.6 mm, i.d., a detector (Beckman, model 163 variable wavelength) and an 
integrator (Beckman, model 427). The column was protected by a guard column packed 
with the same packing material. 
Instrumental settings 
Flow rate 1.0 ml/min 
Wavelength 220 nm 
Chart speed 0.5 cm/min. 
Attenuation 32 
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3.2.2.2 Mobile phase 
A tetraethylammonium phosphate buffer (about 0.05M) was first prepared by 
mixing 23 ml of 25% tetraethylammonium hydroxide in methanol and 10 ml of 85% 
phosphoric acid in 500 ml of re-distilled water, adjusting to p H 2.0 with 25% 
tetraethylammonium hydroxide in methanol, and diluting to 1 litre with re-distilled 
water. 
The mobile phase was prepared by mixing 525 ml of tetraethylammonium 
phosphate buffer with 250 ml of methanol. 
3.2.3 Reagents 
A l l drugs were of Pharmacopoeial or equivalent purity, and were used without 
further purification. A i l other reagents were of analytical grade. 
3.2.3.1 Internal standard solution 
A n aqueous internal standard solution of diphenhydramine hydrochloride (214 
Mg/ml) was prepared by dissolving exactly 0.0107 g of the compound (Sigma Chemical 
Co.) in 50 ml of sulphuric acid (O.IM) in a calibrated flask. 
3.2.3.2 Stock solutions of the alkaloids 
Stock solution of atropine sulfate (200 Mg/ml) was prepared by weighing exactly 
0.01 g of atropine sulfate monohydrate (Janssen Chimica) in 50 ml of sulphuric acid 
(O.IM) in a calibrated flask. 
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Similarly, stock solutions of homatropine hydrobromide (200 Mg/ml), hyoscine 
hydrobromide (200 Mg/ml), and hyoscyamine sulfate (200 Mg/ml) were prepared by 
dissolving appropriate amounts of the corresponding compounds (Sigma Chemical Co.) 
in 50 ml of sulphuric acid (O.IM) in V-flasks. 
3.2.4 Standard Solutions of the Alkaloids 
Standard solutions of each alkaloids (4-50 / ig/ml) were prepared by appropriate 
dilution of the corresponding stock solution with sulphuric acid (O.IM) in 25-ml 
calibrated flasks containing exactly 1 ml of the internal standard solution. 
3.2.5 Preparation of Sample Solution* 
？>2.5.1 Atropine Sulfate or Hyoscyamine Sulfate Tablets 
Ten tablets of atropine sulfate (or two tablets of hyoscyamine sulfate) were 
weighed accurately and powdered finely. An amount equivalent to about 0.25 mg of 
atropine sulfate (or hyoscyamine sulfate) was weighed accurately and dissolved in about 
20 ml of sulphuric acid (O.IM), and then shaken in an ultrasonic bath, with addition 
of ice to the bath, for about 15-30 min. The mixture was filtered and the filtrate was 
collected and transferred into a 25-ml V-flask containing 1 ml of the internal standard 
solution, and finally diluted to mark with sulphuric acid (O.IM). 
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32.52 Atropine Sulfate Injections or Atropine Sulfate Eye Drops 
The Atropine Sulfate Eye Drop samples were first diluted with O.IM sulphuric 
acid so that the concentrations of atropine sulfate were about 0.2 mg/ml (Solution I). 
An accurately measured volume of Solution I or the Atropine Sulfate Injection, 
equivalent to 1 mg of atropine sulfate, was transferred to a 25-ml calibrated flask, 
followed by the addition of 1 ml of the internal standard solution, and then diluted to 
the mark with sulphuric acid (O.IM). 
3.2.5.3 Homatropine Hydrobromide Eye Drops 
The Homatropine Hydrobromide Eye Drop samples were first diluted with O.IM 
sulphuric acid so that the concentrations of homatropine hydrobromide were about 0.2 
mg/ml (Solution I). An accurately measured volume of Solution I，equivalent to 0.8 mg 
of homatropine hydrobromide, was transferred to a 25-ml calibrated flask followed by 
the addition of 1 ml of the internal standard solution, and diluted to the mark with 
sulphuric acid (O.IM). 
•No real samples with hyoscine hydrobromide was available for assay, however, a 
synthetic sample with hyoscine hydrobromide was determined by the proposed method 
and the result was shown in the section of Recovery Test. 
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3.2.6 Quantitative Determination of the Alkaloids Under Study in Various 
Pharmaceutical Preparations 
An aliquot (3 ml) of the sample or standard solution was pipetted into a 
separating funnel followed by the addition of 1 ml of sodium hydroxide solution (1 M). 
The alkaloids in the alkaline aqueous solution was immediately extracted with 10 ml 
of chloroform and shaken for one minute. The organic layer was transferred, via a 
funnel containing 2-3 grams of anhydrous sodium sulphate supported by a filter paper 
(NO. 5A), into a 10-ml V-flask. The aqueous layer and the sodium sulphate were 
washed with small volumes of chloroform, and the washings were collected and 
transferred into the same V-flask. The solution in the V-flask was then evaporated to 
dryness under a stream of nitrogen in a water bath at a temperature of 30-35 °C. The 
residue was dissolved in 100 /xl of chloroform, and kept cool by ice in order to avoid 
evaporation of solvent, and 2.0 /il of the resulting solution was injected onto the 
chromatograph with a 10-/il Hamilton syringe under the chromatographic conditions 
mentioned previously. The injection were performed in duplicate. 
The calibration graph was obtained by plotting the peak area ratios (alkaloid to 
internal standard) against the concentrations of the alkaloid in the aqueous standard 
solutions. 
The amount of each alkaloid in the sample was deduced from the respective 
calibration graph. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 Choice of Extraction Medium 
Other than the alkaloids of interest, other excipients may be present in various 
pharmaceutical preparations, such as preservative(s) in eye drops and injections, 
stabilizer(s) in tablets, and/or other active ingredients. In order to develop a successful 
gas-liquid chromatographic method for the determination of the alkaloids under study, 
an efficient extraction method was essential to separate them from the excipients present 
in samples. 
The alkaloids of interest were suggested to be extracted by organic solvent from 
alkaline media^^. Hence, sodium hydroxide ( IM) was used to provide an alkaline 
medium before extraction. It is important to extract the alkaloids immediately from the 
aqueous solution with the organic solvent after addition of the base because the 
alkaloids can easily be decomposed under a base-assisted esterification process. Several 
organic solvents, including chloroform, dichloromethane, diethylether, and hexane, were 
assessed for their suitability as the extraction medium. 
An aqueous standard solution, which contained known amounts of atropine 
sulfate (7.98 Mg/ml), homatropine hydrobromide (138.6 fig/ml), hyoscine hydrobromide 
(285.3 /ig/ml), and the internal standard solution (30.96 /xg/ml), was prepared. A 3-ml 
aliquot of the aqueous standard solution was made alkaline with sodium hydroxide 
( IM) and extracted with 20 ml of each solvent for 3 min. The organic layer was 
transferred to a V-flask via a funnel containing anhydrous sodium sulphate. The final 
solution, including the washings, was evaporated to dryness under nitrogen in a warm 
water bath (30-35 °C). Al l the residue was dissolved in 100 /A of chloroform, 2.0 /xl of 
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which was injected onto the chromatograph under the chromatographic conditions 
described previously. The peak area ratios (alkaloid to internal standard) in various 
organic solvents are shown in Table 3.3.1-1. Because the peak area ratios so obtained 
were directly proportional to the amounts of alkaloids extracted from the aqueous to 
the organic phase, these ratios were used to compare the extraction capacity of each 
solvent. 
From Table 3.3.1-1，it was found that the extraction capacities of chloroform 
and dichloromethane for each alkaloid were comparable, except for atropine sulfate, 
while hexane was the poorest extraction medium. It was expected that the extraordinary 
high signal of atropine obtained by extraction with dichloromethane would result in a 
much better sensitivity than that of chloroform. The calibration graphs of atropine 
sulfate obtained by extraction with chloroform and dichloromethane were then 
compared, which are shown in Figure 3.3.1-1. Figure 3.3.1-1 indicated that the slopes of 
both calibration graphs were similar, which meant that there was no significant 
difference in the sensitivities of atropine sulfate obtained by extraction with either 
solvent. Besides, the calibration graph obtained with dichloromethane as extraction 
medium exhibited a very large positive intercept, which was suspected to be the cause 
of the extraordinary high signal of atropine. Since the extraction capacities of chloroform 
and dichloromethane for each alkaloid were similar, and the former gave zero intercepts 
in calibration graphs for the alkaloids, chloroform was chosen to be the extraction 
medium for the subsequent determinations. 
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Table 3.3.1-1 Peak area ratios (individual alkaloid to internal standard) after extraction 
with various solvents. 
Extraction Peak area ratios of the alkaloids in the mixture* 
medium 
Atropine Homatropine Hyoscine 
sulfate HBr HBr 
Chloroform 0.1527 2.546 1.939 
Dichloromethane 1.679 2.500 1.942 
Diethylether 0.1135 1.803 1.496 
Hexane 0.04526 1.037 0.07727 
The concentrations of the alkaloids in aqueous standard solution were as follows: 
1. Atropine sulfate ( 7.98 Mg/ml); 
2. Homatropine hydrobromide (138.6 Mg/ml); 
3. Hyoscine hydrobromide (285.3 Mg/ml). 
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Figure 3.3.1-1 Comparison of the calibration graphs of atropine sulfate obtained by 
extraction with chloroform and dicWoromethane, separately. 
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3.3.2 Optimisation of the volume of extraction medium and the shaking time 
In order to save time and simplify the extraction procedure, a single extraction 
was proposed. Because the extraction was only performed once, the volume of extraction 
medium and the shaking time of the extraction became very critical. 
An aqueous standard solution containing known amounts of atropine sulfate 
(11.66 Mg/ml), homatropine HBr (23.76 /ig/ml), hyoscine HBr (48.91 ^g/ml), and 
internal standard was prepared. Aliquots (3 ml) of the aqueous standard solution were 
made alkaline and extracted separately with 10，15 and 20 ml of chloroform at a fixed 
shaking time of 3 min. The organic layer was collected after being dried with anhydrous 
sodium sulphate, and evaporated to dryness under nitrogen. The residue was dissolved 
in 100 111 of chloroform, 2.0 /i l of which was injected into the chromatograph. The peak 
area ratios (alkaloid to internal standard) obtained using various extraction volumes 
are shown in Table 3.3.2-1. From which, it can be seen that there was no significant 
difference in the peak area ratios as the volume of the extraction medium varied. For 
economic reasons, 10 ml of chloroform was used in the subsequent extraction procedure. 
Similarly, the shaking time of the extraction was also optimised. The alkaloids 
in the aqueous standard solution was extracted with 10 ml of chloroform but using 
different shaking times, namely, 1，3, and 5 minutes, the extraction procedure being the 
same as above. The effect of shaking time of extraction on the peak area ratios of the 
alkaloids is shown in Table 3.3.2-2. The results indicated that the peak area ratios was 
also not affected by the shaking time. In order to save time, the shaking time of 1 min. 
was chosen. 
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Table 3.3.2-1 Effect of the volume of chloroform used for extraction on the peak area 
ratios (individual alkaloid to internal standard), the shaking time being 
3 min. 
Compound Peak area ratios of the alkaloids in the mixture 
Extraction volume used, ml 
10 15 20 
Atropine sulfate 1.283 1.277 1.346 
Homatropine HBr 2.380 2.369 2.359 
Hyoscine HBr 3.874 3.892 3.839 
•The concentrations of the alkaloids in aqueous standard solution were as follows: 
1. Atropine sulfate (11.66 Mg/ml); 
2. Homatropine hydrobromide (23.76 /xg/nil); 
3. Hyoscine hydrobromide (48.91 fig/ml). 
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Table 3.3.2-2 Effect of the shaking time on the peak area ratios (individual alkaloid to 
internal standard), the volume of chloroform being 10 ml. 
Compound* Peak area ratios of the alkaloids in the mixture 
Shaking time used, min. 
1 3 5 
Atropine sulfate 2.452 2.414 2.399 
Homatropine HBr 4.555 4.551 4.434 
Hyoscine HBr 7.438 7.378 7.439 
•The concentrations of the alkaloids in aqueous standard solution were as follows: 
1. Atropine sulfate (19.44 /ig/ml); 
2. Homatropine hydrobromide (39.60 /xg/ml); 
3. Hyoscine hydrobromide (81.52 /ig/ml). 
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3.3.3 Choice of stationary phase 
As atropine is a mixture of ( + )- and (-)-hyoscyamine, both compounds may be 
viewed to be the same in terms of chromatographic behaviour. Thus, only the alkaloids 
of atropine, homatropine and hyoscine needed to be resolved. In general, it is not 
difficult to find a suitable stationary phase for separating these three compounds, 
however, the problem became harder if the compounds are unstable to heat. It was 
earlier known that the alkaloids under study might be decomposed on the column^ 
The proper choice of stationary phase became very important because not only was it 
necessary to have good resolution for the alkaloids under study, but also the 
decomposition of the compounds needed to be minimized. 
Several stationary phases on Supelcoport (80/100 mesh), including 3% OV-7, 
3% OV-25, and 3% OV-225, were evaluated. The composition, McReynolds constants, 
and temperature limits of these stationary phases are shown in Table 3.3.3-1. Because 
of their high maximum temperature limits, they are suitable for separating these non-
volatile alkaloids under study. The large difference in McReynolds Constants of various 
stationary phases indicated that their resolution power will not be the same. The 
retention times, peak shapes of the alkaloids under the specified chromatographic 
conditions for each column are listed in Table 3.3.3-2 to Table 3.3.3-4, and the 
respective chromatograms of the alkaloids are shown in Figure 3.3.3-1 to Figure 
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Table 3.3.3-1 The specifications of various stationary phases*. 
Phase Composition Temperature McReynolds constants** 
limit (。C) 
Min./Max. X， Y， Z， U' S， 
OV-7 Phenyl methyl 0/350 69 113 111 171 128 
dimethyl, 
20% phenyl 
OV-25 Phenyl methyl 0/350 178 204 208 305 280 
diphenyl, 
75% phenyl 
OV-225 Cyanopropylmethyl 0/265 228 369 338 492 386 
-phenyl methyl 
•Reference : SUPELCO, International Catalog 25，1987，pp.88. 
••Test solutes : X' = benzene; 
Y' 二 1-bmanol; 
Z， = methyl-n-propyl ketone; 
U， = nitromethane; and 
S' = pyridine. 
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Table 3.3.3-2 The retention times and peak shapes of the alkaloids under study in 
column of 3% OV-7 under the specified conditions 
Compounds Retention t imes*， Relative peak Remarks 
min. area ratio 
Atropine A: 3.17 (s) A: 7.4 Multi-peak, 
sulfate/ B: 3.88 (s) B: 5.5 decomposition 
hyoscyamine C: 5.26 (s) C: 1.0 occurred, 
sulfate** 
Homatropine 4.18 (s) nil Single peak, 
HBr no 
decomposition. 
Hyoscine HBr A: 4.27 (s) A: 1.5 Multi-peak, 
B: 4.96 (s) B: 1.0 decomposition 
occurred. 
+Chromatographic conditions used : 
Column used : 3% OV-7 (5ft. x 2 mm i.d.) 
on Supelcoport (80/100 mesh); 
Initial temperature : 190 °C (1 min.); 
Heating rate : 10 °C/min.; 
Final temperature : 265 °C (1 min.). 
•Peak shape enclosed in parentheses: s，sharp. 
••Atropine sulfate and hyoscyamine sulfate had the same retention time and peak shape. 
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Figure 3.3.3-lGas chromatograms of the alkaloids obtained by using column of 
3% OV-7 under the conditions mentioned in Table 3.3.3-2. 
Atropine/ Homatropine Hyoscine 
hyoscyamine 
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Table 3.3.3-3 The retention times and peak shapes of the alkaloids under study in 
column of 3% OV-25 under the specified conditions+ . , 
Compounds Retention t imes*， Relative peak Remarks 
min. area ratio 
Atropine A: 5.98 (s) A: 16.0 Multi-peak, 
sulfate/ B: 6.89 (s) B: 8.5 decomposition 
hyoscyamine C: 8.65 (s) C: 1.0 occurred, 
sulfate** 
Homatropine 7.26 (s) nil Single peak, 
HBr no 
decomposition. 
Hyoscine HBr A: 7.54 (s) A: 3.2 Multi-peak, 
B: 8.36 (s) B: 1.0 decomposition 
occurred. 
+Chromatographic conditions used : 
Column used : 3% OV-25 (5ft. x 2 mm i.d.) 
on Supelcoport (80/100 mesh); 
Initial temperature : 170 (1 min.); 
Heating rate : 10 °C/min.; 
Final temperature : 265 °C (1 min.). 
•Peak shape enclosed in parentheses: s，sharp. 
••Atropine sulfate and hyoscyamine sulfate had the same retention time and peak shape. 
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Figure 3.3.3-2Gas chromatograms of the alkaloids obtained by using column of 
3% OV-25 under the conditions mentioned in Table 3.3.3-3. 
Atropine/ Homatropine Hyoscine 
hyoscyamine 
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Table 3.3.3-4 The retention times and peak shapes of the alkaloids under study in 
column of 3% OV-225 under the specified conditions+ . 
Compounds Retention t imes*， Relative peak Remarks 
min. area ratio 
Atropine A: 3.72 (s) A: 1.1 Multi-peak, 
sulfate/ B: 4.32 (s) B: 1.0 decomposition 
hyoscyamine C: 6.89 (s) C: 8.8 occurred, 
sulfate** 
Homatropine 5.45 (s) nil Single peak, 
HBr no 
decomposition. 
Hyoscine HBr A: 5.76 (s) A: 1.2 Multi-peak, 
B: 6.34 (s) B: 1.0 decomposition 
C: 10.37 (s) C: 6.8 occurred. 
+ Chromatographic conditions used : 
Column used : 3% OV-225 (5ft. x 2 mm i.d.) 
on Supelcoport (80/100 mesh); 
Initial temperature : 200 (1 min.); 
Heating rate : 10 °C/min.; 
Final temperature : 250 °C (1 min.). 
•Peak shape enclosed in parentheses: s, sharp. 
••Atropine sulfate and hyoscyamine sulfate had the same retention time and peak shape. 
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Figure 3.3.3-3Gas chromatograms of the alkaloids obtained by using column of 
3% OV-225 under the conditions mentioned in Table 3.3.3-4. 
Atropine/ Homatropine Hyoscine 
hyoscyamine 
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From Figure 3.3.3-1 to Figure 3.3.3-3, it was found that all the alkaloids under 
study, except homatropine, were most likely decomposed on the columns because of 
the observation of multi-peak for individual alkaloid. The decomposition products were 
expected to have a shorter retention time than that of the original compound. For 
example, Peak C shown on the chromatograms of atropine/hyoscyamine in various 
types of column might be the peak of the original compound while Peak A and Peak B 
were suspected due to the decomposition products. The relative peak area ratios (shown 
on Table 3.3.3-2 to Table 3.3.3-4) of these peaks illustrated the degree of decomposition 
of the compound in various types of column. Say, for atropine/hyoscyamine, the relative 
peak area ratios of Peak A and Peak B were greater than that of Peak C in the columns 
packed with 3% OV-7 or 3% OV-25, however, the relative peak area ratio of Peak C 
became dominant in the column of 3% OV-225. Similar observations were obtained for 
hyoscine obtained using various types of column. It is apparent that the degree of 
decomposition of the alkaloids on the column packed with 3% OV-225 was the least. 
As a result, the stationary phase of 3% OV-225 was chosen for further study. 
Walters et reported that the decomposition of atropine could be avoided by 
using very little glass wool or none at all at the injection site end of the column. Thus, 
the glass wool at the injection site of the column packed with 3% OV-225 was removed. 
After removal of the glass wool, the retention times and peak shapes of the alkaloids 
under the optimised chromatographic conditions are listed on Table 3.3.3-5, and the 
typical chromatogram of the alkaloids were shown in Figure 3.3.3-4, where no small 
peaks was observed preceding the peaks of atropine, homatropine and hyoscine. Thus, 
the decomposition problem of the alkaloids in the column of 3% OV-225 seemed to be 
mainly due to the decomposition at the injection site and could be avoided by the 
removal of glass wool at the site. Finally, a column packed with 3% OV-225 and with 
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no glass wool at the injection site was used for subsequent determinations。 
Table 3.3.3-5 The retention times and peak shapes of the alkaloids under study in 
column of 3% OV-225 (without injection site glass wool) under the 
optimised conditions+ • 
Compounds Retention t imes*， Relative peak Remarks 
min. area ratio 
Homatropine 3.41 (s) nil Single peak, 
HBr no 
decomposition. 




Hyoscine HBr 6.71 (s) nil Single peak, 
no 
decomposition. 
+ Chromatographic conditions used : 
Column used : 3% OV-225 (5ft. x 2 mm i.d.) 
on Supelcoport (80/100 mesh); 
Initial temperature : 220 °C (1 min.); 
Heating rate : 15 °C/min.; 
Final temperature : 260 °C (4 min.). 
•Peak shape enclosed in parentheses: s, sharp. 
••Atropine sulfate and hyoscyamine sulfate had the same retention time and peak shape. 
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Figure 3.3.3-4Typical chromatogram of the alkaloids obtained by using column of 3% 
OV-225 (without injection site glass wool) under the optimised conditions 
with A, diphenhydramine HCl (internal standard, 8.56 pg/ml) ; B, 
homatropine HBr (34.50 Mg/ml); C, atropine sulfate (31.94 /ig/mJ); and 







‘ * 0 4 8 MIN. 
^Enclosed in parentheses was concentration before extraction. 
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3.3.4 Optimisation of The Instrumental Parameters 
In gas chromatography, several instrumental parameters needed to be optimised: 
such as the flow rate of carrier gas, flow rates of hydrogen and air for the FID detector, 
and temperature programming conditions. Same as discussed in Chapter 2, the flow rate 
of carrier gas, nitrogen, was set to 30 ml/min, which is a common flow rate for analysis 
of drugs. In addition, the flow rates of hydrogen and air were optimised at 30 and 300 
ml/min., respectively. After choosing the best stationary phase, the conditions of the 
temperature programming were optimised as followings. 
An aqueous standard solution containing atropine sulfate (97.20 Mg/ml), 
homatropine hydrobromide (198.0 Mg/ml) and hyoscine hydrobromide (407.6 /ig/ml) was 
prepared (Standard I). Standard I was diluted to 3.6，5.0, 8.3，and 25 folds with sulphuric 
acid (0.1 M) in 25-ml V-flasks which contained 1 ml of the internal standard (Standards 
II). A series of standard solutions for injection were prepared from Standards I I 
following the procedure described in the Experimental section. By fixing the initial and 
final temperature, the heating rate of the temperature programming was first optimised. 
For each heating rate, the extracted standard solutions were injected, and the calibration 
graph for each alkaloid was obtained. The effect of the heating rate on the slopes of the 
calibration graphs of the alkaloids are listed in Table 3.3.4-1. The change in the heating 
rate had no significant effect on the slopes of the calibration graphs (or sensitivities) of 
the alkaloids, however, the overall running time was slightly shorter at increasing heating 
rate. In order to obtain the shortest overall running time, a heating rate of 15 °C/min. 
was selected. 
With fixed initial temperature and the optimised heating rate, the final 
temperature of the temperature programming was optimised. The effect of the final 
temperature on the slopes of the calibration graphs of the alkaloids is shown on Table 
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3.3.4-2. The slopes of the alkaloids were seen to gradually increase with increasing final 
temperature. Thus, a final temperature of 260 °C was chosen since it offered the best 
sensitivities for the alkaloids and the fastest overall running time. 
After fixing the heating rate and final temperature, the optimisation of the initial 
temperature of the temperature programming was performed. The slopes of the 
calibration graphs of the alkaloids are shown on Table 3.3.4-3, where it can be seen 
that the slopes markedly increased with an increase in the initial temperature. Besides, 
the overall running time was also shortened when a higher initial temperature was 
employed. As a consequence, the initial temperature of 220 °C was chosen in order to 
gain a better response of the alkaloids and a shorter overall running time. 
In order to evaluate the performance (or reproducibility) of the optimised 
temperature programming, a chloroform solution containing the alkaloids of atropine, 
homatropine, and hyoscine was prepared and injected ten times onto the column under 
the optimised chromatographic conditions, and the relative standard deviation of the 
peak area ratios for each alkaloid was then calculated. The results are shown in Table 
3.3.4-4. The reproducibility of the optimised temperature programming can be 
considered as good because the relative standard deviation of each alkaloid ranged 
from 1.48 to 3.25%. 
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Table 3.3.4-1 Effects of the heating rate of the temperature programming on the slopes 
of the calibration graphs of the alkaloids with fixed initial and final 
temperature*. 
Slopes of the calibration graphs, ml/fig** 
Compounds 
Heating rate，°C/min 
10 12 15 
Atropine sulfate 0.09376 0.09353 0.09405 
(5.60) (5.30) (5.00) 
Homatropine HBr 0.08498 0.08513 0.08576 
(436) (4.20) (4.02) 
Hyoscine HBr 0.06950 0.06967 0.07016 
(8.17) (7.77) (7.35) 
•The initial temperature was kept at 210 °C for 1 min.; and the final temperature was 
kept at 260 °C for 4 min. 
••Enclosed in parentheses was the retention time in minute. 
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Table 3.3.4-2 Effects of the final temperature of the temperature programming on the 
slopes of the calibration graphs of the alkaloids with fixed initial 
temperature and heating rate,. 
Slopes of the calibration graphs, ml//ig** 
Compounds 
Final temperature, °C 
250 255 260 
Atropine sulfate 0.09105 0.09299 0.09405 
(5.13) (5.04) (5.00) 
Homatropine HBr 0.08406 0.08576 0.08775 
(4.04) (4.02) (4.02) 
Hyoscine HBr 0.06875 0.06933 0.07016 
(8.25) (7.74) (7.35) 
•The initial temperature was kept at 210 for 1 min.; and the heating rate was kept 
at 15 °C/min. 
••Enclosed in parentheses was the retention time in minute. 
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Table 3.3.4-3 Effect of the initial temperature of the temperature programming on the 
slopes of the calibration graphs of the alkaloids with fixed final 
temperature and heating rate'. 
Slopes of the calibration graphs, ml//xg** 
Compounds 
Initial temperature, °C 
200 210 220 
Atropine sulfate 0.09045 0.09405 0.1064 
(5.70) (5.00) (4.30) 
Homatropine HBr 0.08058 0.08576 0.09837 
(4.71) (4.02) (3.37) 
Hyoscine HBr 0.06510 0.07016 0.07791 
(8.08) (7.35) (6.65) 
•The final temperature was kept at 260 for 4 min.; and the heating rate was kept 
at 15 °C/inin. 
••Enclosed in parentheses was the retention time in minute. 
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Table 3.3.4-4 Data for testing the reproducibility of the optimised temperature 
programming. 
Compounds Concentration Relative standard 
in aqueous, deviation* 
Mg/ml (%) 
Atropine sulfate 31.94 2.04 
Homatropine HBr 34.50 1.83 
Hyoscine HBr 34.56 1.48 
Hyoscyamine sulfate 32.64 3.25 
*For ten replicate injections. 
3.3.5 Preparation of the calibration graphs 
The calibration graph of each alkaloid under study was obtained by plotting the 
peak area ratios (alkaloid to internal standard) against the corresponding concentrations 
in aqueous standard solutions. In quantitative determination of the alkaloids, results 
were deduced from the calibration graphs with the help of the linear regression 
equations. 
An aqueous standard solution, which contained atropine sulfate (199.2 /^g/ml), 
homatropine hydrobromide (204.8 /ig/ml) and hyoscine (199.2 Mg/ml), was prepared by 
mixing appropriate amounts of the respective stock solutions in 50-ml calibrated flask 
(Standard I). Aliquots of 0.5，1.0, 2.0，4.0, 6.0, 8.0, 10.0 and 13.0 ml of Standard I were 
diluted separately to 25-ml with sulphuric acid (O.IM) in calibrated flasks containing 
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1 ml of the internal standard solution (Standard II). Aliquot (3 ml) of Standard I I was 
made alkaline with sodium hydroxide (1 M) and extracted with 10 ml of chloroform and 
hand shaken for 1 min. The organic layer was transferred, via a funnel containing 
anhydrous sodium sulphate, into a volumetric flask. The filtrate was evaporated to 
dryness under a stream of nitrogen in a warm water bath (30-35 °C). The residue was 
dissolved in 100 ul of chloroform, 2.0 i i l of which was injected onto the chromatograph 
under the optimised conditions. The injection was performed in duplicate. The 
calibration graph for each alkaloid was obtained by plotting the peak area ratios 
(alkaloid to internal standard) against the corresponding concentrations in aqueous 
standard solution. 
Similarly, the calibration graph of hyoscyamine sulfate was prepared with 
procedure described above. 
The data for the calibration graphs of the alkaloids are listed in Table 3.3.5-1 to 
Table 3.3.5-4, and the respective calibration graphs are shown in Figure 3.3.5-1 to 
Figure 3.3.5-4. 
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Table 3.3.5-1 Data on the calibration graph of atropine sulfate. 
Aqueous concentrations Mean peak area 
of atropine sulfate, ratios 









Linear working range = 4 - 104 ^g/ml; 
Slope = 0.1347 ml//ig； 
Intercept = 0.001790; 
Correlation coefficient = 0.9999; 
Detection limit" 二 4.0 Mg/ml. 
•The least detectable amount of alkaloid in aqueous samples. 
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Table 3.3.5-2 Data on the calibration graph of homatropine hydrobromide. 
Aqueous concentrations Mean peak area 
of homatropine HBr, ratios 









Linear working range = 4 - 107 /xg/ml; 
Slope = 0.1232 ml/Mg； 
Intercept = -0.06916; 
Correlation coefficient = 0.9999; 
Detection limit = 4.0 /xg/ml. 
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Figure 3.3.5-2 Calibration graph of homatropine hydrobromide. 
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Table 3.3.5-3 Data for the calibration graph of hyoscine hydrobromide. 
Aqueous concentrations Mean peak area 
of hyoscine HBr, ratios 









Linear working range = 4 - 104 /xg/ml; 
Slope = 0.09745 ml/^g； 
Intercept 二 -0.1171; 
Correlation coefficient = 0.9998; 
Detection limit = 4.0 Mg/ml. 
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Figure 3.3.5-3 Calibration graph of hyoscine hydrobromide, 
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Table 3.3.5-4 Data for the calibration graph of hyoscyamine sulfate. 
Aqueous concentrations Mean peak area 
of hyoscyamine sulfate, ratios 









Linear working range = 4 - 1 1 2 Mg/ml; 
Slope - 0.1497 ml/Mg； 
Intercept 二 -0.08476; 
Correlation coefficient = 0.9999; 
Detection limit = 4.0 /xg/ml. 
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Figure 3.3.5-4 Calibration graph of hyoscyamine sulfate. 
目 
p n ： 




1 1 1 o 
^ ^ o o 
SOpBJ BaJB 
117 
3.3.6 Recovery Test and Precision 
The reliability of the proposed method was checked by performing the recovery 
tests on the alkaloids under study. The recovery tests were done by adding known 
amount of each alkaloid to tablet where it was known to be absent. For each alkaloid, 
four replicate determinations were performed, and the detailed procedure was described 
below. 
An aqueous standard solution containing known amounts of atropine sulfate 
(199.6 Mg/ml), homatropine hydrobromide (215.6 Mg/ml) and hyoscine hydrobromide 
(216.0 Atg/ml) was prepared (Standard I). A series of aqueous standard solutions 
containing the internal standard was prepared from Standard I (Standard II). A 3-ml 
aliquot of Standard I was pipetted into a beaker containing about 0.5 g of finely 
powdered tablet where the alkaloids were absent, and the mixture was made up to 
about 20 ml with sulphuric acid (O.IM) and shaken in an ultrasonic bath for 15-30 min. 
The mixture was filtered, and the filtrate was diluted to 25 ml with sulphuric acid (O.IM) 
in a calibrated flask containing 1 ml of the internal standard solution (Sample I). 
A 3-ml aliquot of Sample I or Standard I I was made alkaline with sodium 
hydroxide ( IM ) and extracted with 10 ml of chloroform and hand shaken for 1 min. The 
organic layer was transferred, via a funnel containing anhydrous sodium sulphate, into 
a volumetric flask. The filtrate was evaporated to dryness under nitrogen. The residue 
was dissolved in 100 i^l of chloroform, and 2.0 ii\ of which was injected on to the 
chromatograph under the optimised conditions. The amount of each alkaloid in Sample 
I was deduced from the respective calibration graph. The recovery test of hyoscyamine 
sulfate was performed in a similar way. The percentage recoveries are listed in Table 
3.3.6-1. The mean results of four analyses ranged from 95.93 to 102.1%. 
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The precision of the proposed method was checked by calculating the relative 
standard deviation for the above determinations, and the results are also present in 
Table 3.3.6-1. The relative standard deviation of four analyses for each alkaloid under 
study ranged from 1.1 to 2.5%. 
Table 3.3.6-1 Results of the recovery tests and precision for the alkaloids under study 
using the proposed method. 
Drug Amount added Recovery* Mean recovery Relative standard 
(mg/5 ml) (%) (%) deviation (%) 
Atropine 23.95 102.0 
sulfate 102.8 
103.1 102.1 1.1 
100.3 
Homatropine 25.87 98.57 
HBr 100.2 
98.88 98.49 1.4 
96.29 
Hyoscine HBr 25.92 99.69 
100.8 
102.4 101.5 1.3 
103.1 
Hyoscyamine 24.48 94.82 
sulfate 94.91 
93.87 95.93 2.5 
100.1 
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3.3.7 Determination of The Alkaloids in Various Pharmaceutical Preparations 
The contents of the alkaloids under study in seven commercially available 
pharmaceutical preparations were analysed in triplicate using the proposed method. 
The results obtained were compared with those obtained using an established HPLC 
method? and with the corresponding label values. A brief description of each of the 
sample was shown in Table 3.3.7-1. The assay results are listed in Table 3.3.7-2. Typical 
chromatograms for sample No.3, 6 and 7 are shown in Figure 3.3.7-1 to Figure 3.3.7-3, 
where no extra peaks due to other excipients were detected. 
The average assay results of the proposed method were generally agreed with 
those obtained using the counter-check HPLC method and with the corresponding label 
values. 
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Table 3.3.7-1 Brief description of the samples. 
Batch Name* Source Ingredients Labelled 
No. amount 
(mg/tablet) 
1 ATROPINE Commercially Atropine sulfate 1 % 
(Eye drop) available Benzalkonium 
chloride 0.01 % 
Hydroxypropyl-
methylcellulosum 
2 LOMOTIL Private Atropine sulfate 0.025 
(Tablet) doctor Diphenoxylate HCl 2.5 
3 LOMOTIL Commercially Atropine sulfate 0.025 
(Tablet) available Diphenoxylate HCl 2.5 
4 LOMOFEN Commercially Atropine sulfate 0.025 
(Tablet) available Diphenoxylate HCl 2.5 
Furazolidone 50.0 
5 (Injection) University Atropine 0.6 mg/ml 
Health Centre sulfate 
CUHK 
6 (Eye drop) University Homatropine HBr 2 % 
Health Centre or 20 mg/ml 
CUHK 
7 LEVSIN Commercially (-)-Hyoscyamine 0.125 
(Tablet) available sulfate 
*The form of the sample was enclosed in the parentheses. 
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Table 3.3.7-2 The assay results for the determination of the alkaloids under study in 
various pharmaceutical preparations. 
Percentage of label claim 
Batch Ingredients Labelled 
No. values By proposed method 
(mg/tablet) — By HPUC 
amount 女 method 
found mean 
1 Atropine 1 % 89.0 
sulfate 89.6 89.6 (0.5) 92.9 
90.3 
2 Atropine 0.025 99.2 
sulfate 96.9 97.9 (1.0) 94.4 
97.6 
3 Atropine 0.025 97.6 
sulfate 104.8 100.0 (3.4) 100.8 
97.6 
4 Atropine 0.025 99.4 
sulfate 99.5 98.9 (0.83) 95.6 
97.7 
5 Atropine 0.6 mg/ml 114.5 
sulfate 113.6 113.2 (1.3) 111.0 
111.5 
6 Homatropine 2 % 88.5 
HBr 90.0 88.7 (1.0) 90.5 
87.5 
7 Hyoscyamine 0.125 110.1 
sulfate 110.8 108.7 (2.5) 108.8 
105.2 
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Figure 3.3.7-1 The chromatogram of sample No.3, with peaks of A, diphenhydramine 
hydrochloride; and B, atropine sulfate. 
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Figure 3.3.7-2 The chromatogram of sample No.6, with peaks of A, diphenhydramine 
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Figure 3.3.7-3 The chromatogram of sample No.7, with peaks of A, diphenhydramine 
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3.4 CONCLUSION 
A simple, efficient, and accurate gas-liquid chromatographic method for the 
simultaneous determination of atropine (or hyoscyamine), homatropine and hyoscine 
in pharmaceutical preparations has been developed. The proposed method used 
chloroform as the extraction medium, which could extract the alkaloids from various 
pharmaceutical preparations, such as eye drops, injections, and tablets, but not the 
excipients. The proposed extraction method offered the advantages of being fast and 
simple since a single-step extraction with chloroform was used with a shaking time of 
one minute. Besides, the detection limit of the proposed method was down to 4 /ig/ml 
for all alkaloids under study, and thus the proposed method is suited for the assay of 
pharmaceutical preparations containing low levels of the alkaloids. The method has 
been applied successfully and conveniently to the determination of the alkaloids 
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APPENDIX 
MODIFICATION OF AN HPLC METHOD FOR 
DETERMINATION OF GUAIPHENESIN IN 
COUGH-COLD SYRUPS 
A.1 INTRODUCTION 
Guaiphenesin, a common drug found in cough syrup formulations, is used to 
reduce the viscosity of tenacious sputum. Many methods have been established for the 
determination of guaiphenesin in pharmaceutical formulations, such as high performance 
liquid chromatographic (HPLC) and spectrophotometric methods. 
Recently, Lau et al developed a reversed-phase ion-pair HPLC methodi for the 
determination of the active ingredients present in cough-cold syrups, however, the 
method was not found to be suitable for the assay of guaiphenesin because it has a 
very short retention time and its peak is masked by the peaks of the dyes present in 
the syrups. 
In order to overcome the masking effect due to the dyes, the simplest way was 
to remove the dyes from the sample matrix by solvent extraction, however, such 
preliminary procedure wil l complicate the original simple and convenient method. 
Another alternative was to minimize the effect of the dyes by dilution, and it was found 
that the sample solution was nearly colorless and the peak due to the dye(s) was hardly 
seen as the sample was diluted to 300-1000 folds. At such high dilution, the 
concentration of guaiphenesin in the sample solutions was around 20-30 ppm. 
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It was the purpose of the present work to modify the method of Lau et al^  so 
that guaiphenesin in cough-cold syrups can be determined accurately. We have found 
that if the wavelength for the absorbance measurements is set at 274 nm, and the water 
content of the mobile phase is also increased to increase the retention time of 
guaiphenesin to achieve better resolution, it is possible to determine guaiphenesin with 
concentrations around 20 ppm. 
The modified method was used as a counter-check method for the assay of 
guaiphenesin by the proposed GC method. The method was also successfully applied 
to analyse the content of guaiphenesin in five commercially available cough-cold syrups, 
and the results were shown in good agreement with the one obtained using the proposed 
GC method and also the label claimed values. 
A.2 EXPERIMENTAL 
A.2.1 Instumentation 
The liquid chromatograph consisted of a controller (Beckman, model 421A), a 
solvent pump (Beckman, model HOB), an injection system (Altex, 210 valve), an 
analytical column Beckman 5 fi Ultrasphere-ODS 250 x 4.6 mm, i.d., a detector 
(Beckman, model 163 variable wavelength) and an integrator (Beckman, model 427). 
The column was protected by a guard column packed with the same packing material. 
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Instrumental settings 
Flow rate : 1.0 ml/min. 
Wavelength : 274 nm 
Chart speed : 0.5 cm/min. 
Attenuation : 16 
A.2.2 Mobile phase 
Composition of the mobile phase : 
Original New 
Methanol 715 ml 635 ml 
Water 234 ml 315 ml 
Tetrahydrofuran 50 ml 50 ml 
Phosphoric acid(85%) 1 ml 1 ml 
Sodium dioctyl-
sulphosuccinate 5.8 g 5.8 g 
pH (adjusted by 
ammonia) 4.6 4.6 
The mobile phase was filtered through a 0.45 fim filter (Millipore). Finally, the 
mobile phase was degassed by suction and sonication, and then it was stored in an air-
tight bottle. 
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A.2.3 Standard solution 
Stock solution of guaiphenesin (504 ppm) was prepared by dissolving accurately 
0.0504 g of the compound in 100 ml of the mobile phase in a volumetric flask. The 
standard solutions (5-30 ppm) were prepared by appropriate dilution of the stock 
solution with the mobile phase. 
A.2.4 Sample solution 
Sample solution I with about 500 - 1000 ppm of guaiphenesin was prepared by 
diluting appropriate amount of sample into 10 ml of the mobile phase in a calibrated 
flask. Sample solution I I (used for injection) containing about 15 - 20 ppm of 
guaiphenesin was prepared by diluting appropriate amount of sample solution I into 
10 ml of the mobile phase in a calibrated flask. 
A l l the standard and sample solutions were filtered with a syringe equipped with 
a piece of 0.45 [im filter paper before injection. 
A.2.5 Assay 
A sample/standard solution (20 ^l) was injected into the system and the signals 
were recorded as peaks and their peak heights recorded by the integrator. 
The calibration graph was plotted with the peak heights of guaiphenesin against 
its corresponding concentrations. The amount of guaiphenesin in each sample was 
deduced by interpolation on the calibration graph. 
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A.3 RESULTS AND DISCUSSION 
A.3.1 Composition of the mobile phase 





it can be seen that guaiphenesin lacks functional groups for protonation so that it cannot 
interact strongly with the ion-pair agent, and its retention time is rather short because 
of its weak interaction with the column material. In order to improve the peak 
resolution between guaiphenesin and other excipients such as dyes, the water content of 
the mobile phase was increased from 23.5 %, v/v to 31.5 %, v/v. Higher percentage of 
water content in the mobile phase can result in increasing the back pressure of the 
column, and thus, the flow rate of the mobile phase was reduced from 1.3 ml/min to 1.0 
ml/min. in order to compensate for the effect of the increasing back pressure. 
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A.3.2 Effect of dilution 
The dilution factor of the samples was optimised in order to successfully reduce 
the interference of the dyes. A real sample was selected and successively diluted to 
10-fold, 20-fold, 33-fold, 100-fold and 333-fold, respectively, with the mobile phase. The 
chromatograms of the diluted samples were obtained using the modified method and are 
shown in Figure A.3.1-1 to Figure A.3.1-5. As the dilution factor of the sample was 
increased, the peak height of Peak B (suspected to be due to the dyes) gradually 
decreased and Peak B finally disappeared at 333-fold dilution. This observation 
suggested that the interference of dyes could be removed at a dilution of 333-fold or 
higher. In fact, the sample solution was seen to be colorless as the sample was diluted 
to 333 - 1000 folds. 
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Figure A.3.1-1 The HPLC chromatogram of a 10-fold diluted sample No.l with 
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Figure A.3.1-1 The HPLC chromatogram of a 10-fold diluted sample No.l with 
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Figure A.3.1-4 The HPLC chromatogram of a 100-fold diluted sample No.l with 
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Figure A.3.1-4 The HPLC chromatogram of a 100-fold diluted sample No.l with 
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Figure A.3.1-4 The HPLC chromatogram of a 100-fold diluted sample No.l with 
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A.3.2 The wavelength for detection 
When the sample was diluted to 300-fold, the concentrations of guaiphenesin 
would be lowered to 15 - 25 ppm. However, the original wavelength for detection (i.e. 
254 nm) was not at the absorbance maximum of guaiphenesin, and not sensitive enough 
to assay guaiphenesin at such low concentrations. Figure A.3.2-1 shows a UV spectrum 
of a standard guaiphenesin solution in the mobile phase, which indicated that the 
maximum absorbance wavelength of guaiphenesin in the mobile phase was at 274 nm. 
In order to enliance the signal of guaiphenesin, the wavelength of the UV detector 
was set at 274 nm. A typical chromatogram of standard guaiphenesin obtained at the 
274 nm was shown in Figure A.3.2-2. The chromatograms of a real sample obtained 
using the original wavelength of 254nin and new wavelength of 274nm are shown in 
Figure A.3.2-3 and Figure A.3.2-4, respectively. The signal of guaiphenesin (Peak G) at 
the new wavelength was much higher. Besides, the resolution between guaiphenesin and 
other excipients was also improved using the new wavelength. 
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Figure A.3.2-1 The UV spectrum of standard guaiphenesin (30.24 ppm) in the 
new mobile phase. 
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Figure A.3.2-2 A typical HPLC chromatogram of standard guaiphenesin (25.20 
ppm). 
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Figure A.3.2-3 The HPLC chromatogram of 333-fold dilution of sample No. 1 
obtained using the original wavelength of 254 nm, with peak of 
guaiphenesin (G). 
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Figure A.3.2-4 The HPLC chromatogram of 333-fold dilution of sample No. 1 
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A.3.3 Calibration graph 
A calibration graph of guaiphenesin was plotted with the peak height of the 
compound against its concentrations using the proposed method, and the graph is shown 
in Figure A.3.3-1. With the help of the linear regression analysis, the slope of the graph 
was found to be 376.9 ppm"'' and the correlation coefficient of the graph was 0.99992. 
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A.3.4 Real sample analysis 
Five cough-cold syrups containing guaiphenesin, which had been previously 
analysed by the proposed GC method, were quantitatively determined using the 
modified method. The results are presented in Table A.3.4. A typical chromatogram of 
sample No. 1 is shown in Figure A.3.2-4. It was found that the peak of guaiphenesin 
was well separated from peaks of other excipients, except peak X. In order to minimize 
the interference due to peak X in measuring the signal of guaiphenesin, the peak height 
of guaiphenesin was measured instead of its peak area. The assay results agreed with 
those obtained by the GC method described in Chapter 2 and also the label claimed 
values. 
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Table A.3.4-1 The assay results for the determination of guaiphenesin in cough 
syrups. 
Sample Labelled Percentage of label claim 
no. value 
(mg/Sml) 




1 (2) 25.0 91.7 
93.7 93.3 (1.2) 96.5 (1.5) 
94.5 
2 (3) 25.0 96.2 
98.0 97.8 (1.3) 98.5 (1.3) 
99.3 
3 (7) 100.0 102.5 
99.1 100.6 (1.4) 103.1 (1.3) 
100.3 
4 (8) 100.0 115.3 
113.1 113.9 (1.0) 111.4 (1.7) 
113.3 
5 (9) 100.0 99.4 
102.3 101.5 (1.5) 97.3 (0.5) 
102.9 
The sample number used in previous GC analysis are enclosed in parentheses. 
••Mean of triplicate measurements, and standard deviation enclosed in parentheses. 
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CONCLUSION 
An established HPLC method，which was originally not suitable for the 
quantitative determination of guaiphenesin in cough-cold syrups, was found to be 
applicable in analysis of guaiphenesin in cough-cold syrups after minor modifications 
of the detector wavelength, dilution factor of the sample solution and the content of 
the mobile phase. High dilution factor (300-1000 folds) of the sample solution could 
minimize the interference due to the dyes. The signal of guaiphenesin was maximised 
by changing the wavelength from 254 to 274 nm. In addition, the increased water 
content of the mobile phase also helped to improve the separation of the peak of 
guaiphenesin from those of other excipients. 
The modified method offered the advantages of convenience and economy to the 
analysts because there is no need to change the column and the reagents, although 
some minor changes in the original method were necessary to suit the analysis of 
guaiphenesin. 
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